



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> :	A3	(11) International Publication Number:	WO 00/34296
C07H 15/08, 15/18, 15/26, A61K 47/48		(43) International Publication Date:	15 June 2000 (15.06.00)

(21) International Application Number:	PCT/US99/29338	(74) Agents:	POLIZZI, Catherine, M. et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).
(22) International Filing Date:	9 December 1999 (09.12.99)		
(30) Priority Data:		(81) Designated States:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
60/111,644	9 December 1998 (09.12.98)	US	
60/160,997	23 October 1999 (23.10.99)	US	
09/457,913	8 December 1999 (08.12.99)	US	
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application			
US	09/457,913 (CIP)		
Filed on	8 December 1999 (08.12.99)		
(71) Applicant ( <i>for all designated States except US</i> ):	LA JOLLA PHARMACEUTICAL COMPANY [US/US]; Suite 300, 6455 Nancy Ridge Drive, San Diego, CA 92121 (US).		
(72) Inventors; and		Published	
(75) Inventors/Applicants ( <i>for US only</i> ):	JACK, Richard, M. [-/US]; 14179 Boquita Drive, Del Mar, CA 92014 (US). JONES, David [-/US]; 11265 Florindo Road, San Diego, CA 92121 (US). YU, Lin [-/US]; 11597 Tree Hollow Lane, San Diego, CA 92128 (US).	With international search report.	
(88) Date of publication of the international search report:			19 October 2000 (19.10.00)

(54) Title: CONJUGATES COMPRISING GALACTOSE ALPHA 1,3 GALACTOSYL EPITOPE AND METHODS OF USING SAME

## (57) Abstract

This invention provides conjugates useful for xenotransplantation which comprise a galactose  $\alpha$ 1,3 galactosyl ( $\alpha$ Gal) epitope conjugated to a valency platform molecule, preferably a chemically defined valency platform molecule which allows precise valency. The invention also provides compositions comprising these conjugates, and methods (such as methods for inducing tolerance) using these conjugates and compositions.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

# INTERNATIONAL SEARCH REPORT

International Application No

US 99/29338

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC 7 C07H15/08 C07H15/18 C07H15/26 A61K47/48

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category <sup>3</sup>	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 33528 A (BIOTRANSPLANT INC) 6 August 1998 (1998-08-06) the whole document ---	1-30
X	WO 98 47915 A (NOVARTIS ERFINDUNGEN VERWALTUNG ; KATOPODIS ANDREAS (CH); NOVARTIS A) 29 October 1998 (1998-10-29) the whole document ---	1-30
A	WO 93 03735 A (ALBERTA RES COUNCIL ; OKLAHOMA BAPTIST MED CENTER (US)) 4 March 1993 (1993-03-04) ---	
A	WO 95 07073 A (JOLLA PHARMA ; COUTTS STEPHEN M (US); JONES DAVID S (US); LIVINGSTON) 16 March 1995 (1995-03-16) ---	
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

<sup>3</sup> Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

14 June 2000

21/06/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040. Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Bardili, W

## INTERNATIONAL SEARCH REPORT

International Application No

/US 99/29338

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 99 52561 A (SCHWARZ ALEXANDER ;BAXTER INT (US); BYRNE GUERARD W (US); DAVIS TH) 21 October 1999 (1999-10-21) figures 1,2,24; example 14 -----	1-30

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

US 99/29338

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
WO 9833528	A	06-08-1998	AU 6319198 A EP 0969872 A WO 0006194 A	25-08-1998 12-01-2000 10-02-2000
WO 9847915	A	29-10-1998	AU 7643998 A EP 0970114 A ZA 9803245 A	13-11-1998 12-01-2000 19-10-1998
WO 9303735	A	04-03-1993	AU 666128 B AU 2505992 A CA 2116138 A EP 0661980 A IL 102916 A IL 120453 A JP 7501237 T US 5695759 A US 5767093 A US 5651968 A	01-02-1996 16-03-1993 04-03-1993 12-07-1995 12-03-1999 06-12-1998 09-02-1995 09-12-1997 16-06-1998 29-07-1997
WO 9507073	A	16-03-1995	US 6060056 A US 5552391 A AU 677710 B AU 7720994 A CA 2171434 A CN 1134109 A EP 0642798 A EP 0722318 A FI 961100 A JP 7126186 A JP 9500389 T NO 960952 A US 5606047 A US 5633395 A	09-05-2000 03-09-1996 01-05-1997 27-03-1995 16-03-1995 23-10-1996 15-03-1995 24-07-1996 08-05-1996 16-05-1995 14-01-1997 02-05-1996 25-02-1997 27-05-1997
WO 9952561	A	21-10-1999	AU 3564599 A	01-11-1999



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>C07H 15/08, 15/18, 15/26, A61K 47/48</b>		A2	(11) International Publication Number: <b>WO 00/34296</b> (43) International Publication Date: 15 June 2000 (15.06.00)
(21) International Application Number: <b>PCT/US99/29338</b>			(74) Agents: POLIZZI, Catherine, M. et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).
(22) International Filing Date: 9 December 1999 (09.12.99)			
(30) Priority Data: 60/111,644 9 December 1998 (09.12.98) US 60/160,997 23 October 1999 (23.10.99) US 09/457,913 8 December 1999 (08.12.99) US			(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 09/457,913 (CIP) Filed on 8 December 1999 (08.12.99)			
(71) Applicant (for all designated States except US): LA JOLLA PHARMACEUTICAL COMPANY [US/US]; Suite 300, 6455 Nancy Ridge Drive, San Diego, CA 92121 (US).			Published <i>Without international search report and to be republished upon receipt of that report.</i>
(72) Inventors; and (75) Inventors/Applicants (for US only): JACK, Richard, M. [-/US]; 14179 Boquita Drive, Del Mar, CA 92014 (US). JONES, David [-/US]; 11265 Florindo Road, San Diego, CA 92121 (US). YU, Lin [-/US]; 11597 Tree Hollow Lane, San Diego, CA 92128 (US).			

(54) Title: CONJUGATES COMPRISING GALACTOSE ALPHA 1,3 GALACTOSYL EPITOPES AND METHODS OF USING SAME

## (57) Abstract

This invention provides conjugates useful for xenotransplantation which comprise a galactose  $\alpha$ 1,3 galactosyl ( $\alpha$ Gal) epitope conjugated to a valency platform molecule, preferably a chemically defined valency platform molecule which allows precise valency. The invention also provides compositions comprising these conjugates, and methods (such as methods for inducing tolerance) using these conjugates and compositions.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

CONJUGATES COMPRISING GALACTOSE ALPHA 1,3 GALACTOSYL EPITOPES  
AND METHODS OF USING SAME

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the priority benefit of provisional applications U.S. Serial  
5 Nos. 60/111,644, filed December 9, 1998, and 60/160,997, filed October 23, 1999, the  
contents of both of which are incorporated by reference in their entirety.

STATEMENT OF RIGHTS TO INVENTIONS MADE UNDER FEDERALLY  
SPONSORED RESEARCH

10 (Not applicable)

TECHNICAL FIELD

This invention relates to the field of xenotransplantation and immunotolerance.  
More specifically, it relates to conjugates of galactose  $\alpha$ 1,3 galactosyl epitope(s) ( $\alpha$ Gal) for  
15 use in reducing levels of circulating anti- $\alpha$ Gal antibodies and inducing immune tolerance to  
xenotransplanted tissue.

BACKGROUND

There is a large and increasing need for organ transplantation, which is exacerbated  
20 by a critical shortage of available human organs for transplant. The possibility of  
employing xenotransplantation to overcome the lack of human organs for  
allotransplantation is a possible solution to the critical organ shortage but in itself presents  
serious problems.

Two basic types of xenografts have been studied. In concordant xenografts, an  
25 organ from a donor animal is transplanted into a similar species which lacks antibodies to  
the donor organ. Rejection of a concordant organ is usually caused by T cell-mediated  
reactivity to differences in major histocompatibility antigens. Concordant  
xenotransplantation had been applied to human patients as early as 1963 with the most  
70 celebrated case being the transplantation of a baboon heart into a human neonate.  
Auchincloss et al. (1998) *Ann. Rev. Immunol.* 16:433. In discordant transplants, the donor  
and recipient are phylogenetically more distant and the recipient has antibodies to the donor

organ as is the case of porcine organs transplanted into Old World primates. These xenografts are rejected within the first few minutes due to the phenomenon of hyperacute rejection (HAR).

In humans and Old World primates, natural antibodies specific for the galactose  $\alpha$ 1,3 galactosyl ( $\alpha$ Gal) epitope mediate both the hyperacute rejection (HAR) and delayed xenograft rejection (DXR) of organs xenotransplanted from animals such as pigs. Humans and Old World primates express high levels of circulating antibodies to galactose  $\alpha$ 1,3 galactosyl ( $\alpha$ Gal) residues which are expressed at high levels on membrane lipids and proteins of other animal species. Galili et al. (1988) *J. Biol. Chem.* 263:17755. This is due to the fact that humans and Old World primates lack the enzyme  $\alpha$ 1,3 galactosyltransferase which is required to express the  $\alpha$ Gal epitope (Sandrin et al. (1993) *Proc. Natl. Acad. Sci. USA* 90:11391) and thus make antibodies to the  $\alpha$ Gal epitope which is expressed on normal gut flora and is recognized as foreign. By contrast, xenograft organ donor species (e.g., pigs) express the  $\alpha$ 1,3 galactosyltransferase enzyme and thus express the  $\alpha$ Gal epitope. It has been estimated that there are approximately  $10^7$   $\alpha$ Gal epitopes per cell on many donor tissue cells. Cooper et al. (1998) *Xenotransplantation* 5:6-17.

When an  $\alpha$ Gal-expressing discordant organ is transplanted into a recipient that produces anti- $\alpha$ Gal antibodies, the first deleterious result is HAR mediated by the high levels (up to 4% of circulating IgM) of the natural anti- $\alpha$ Gal Ig. Parker (1994) *J. Immunol.* 153:3791.  $\alpha$ Gal bearing transplants (porcine islets) into humans have been shown to increase anti- $\alpha$ Gal responses by up to 64-fold. Galili et al. (1995) *Transplantation* 59:1549. Transplantation of pig cartilage into cynomolgus monkeys causes a 30-300 fold increase in IgG anti- $\alpha$ Gal and 2-16 fold increase in IgM. Galili et al. (1997) *Transplantation* 63:646. These natural antibodies bind to  $\alpha$ Gal expressed on the endothelial surfaces of the engrafted organ which both activates the complement system and the endothelium causing damage to the cell and sets up a net prothrombotic state on the vessel surface. The result is a damaged endothelium and massive clotting causing the rapid development of ischemia of the transplanted organ and its functional incapacitation within minutes to hours.

Anti- $\alpha$ Gal antibodies also play a role in delayed xenograft rejection (DXR), the intermediate term (several days) damage to xenotransplanted organs which often results in rejection. Bach et al. (1995) *Nature Med.* 1:869-873. Anti- $\alpha$ Gal antibodies bind to the

endothelium and mediate a plethora of cell-mediated responses such as ADCC, leading to vascular and tissue damage which compromises the function of the transplanted organ.

Anti- $\alpha$ Gal antibodies can also cause chronic activation of receptors on xenograft cells and/or increased immunogenicity of xenograft-specific antigens. Cooper et al. (1998)

5       *Xenotransplantation* 5:6-17. Diminution of anti- $\alpha$ Gal antibodies levels can attenuate this damage, but the damage, even if not acute, is cumulative and can eventually leads to organ rejection.

Various strategies have been pursued to deal with the major sequelae of anti- $\alpha$ Gal antibody binding. These include: 1) inhibition of effector functions mediated, directly or 10 indirectly by anti- $\alpha$ Gal antibodies; 2) depletion of recipient anti- $\alpha$ Gal antibodies; 3) sublethal irradiation and reconstitution of recipient with autologous and donor bone marrow; 4) modification of donor tissue glycosylation; 5) suppression of anti- $\alpha$ Gal antibodies in recipient; and 6) administration of  $\alpha$ Gal moieties found on donor tissue to the recipient.

15       In attempts to inhibit the effector functions mediated by anti- $\alpha$ Gal antibody binding, much effort has been spent to generate donor animals transgenic for complement regulatory proteins such as decay accelerating factor (DAF, CD55), and homologous restriction factor (HRF, CD59). Schmoekel et al. (1996) *Transplantation* 62:729; and Byrne et al. (1997) *Transplantation* 63:149. These proteins, members of the regulators of 20 complement activation (RCA) gene family, can downregulate the generation of complement proteins which mediate acute inflammation and cell lytic activity. Transgenic expression of RCA proteins does nothing, however, to address the effect of anti- $\alpha$ Gal antibodies binding to the endothelium which sets up the net prothrombotic state subsequent to endothelial cell activation. Thus, while RCA-transgenic donor organs may have an 25 ameliorative effect on HAR, this approach will not have an effect on DXR wherein xenograft damage is mediated by effector cells which bind to anti- $\alpha$ Gal antibodies. Further, while the expression of RCA molecules on the transplanted organ may protect the transplant from protective functions of the host/recipient immune response, if the transplanted organ were to express pathogen antigens (from viral or bacterial infection), 30 protective antibody effector function mediated by complement would be effectively shut off leaving the host with an organ full of pathogen-infected cells. For these reasons,

strategies aimed at controlling complement are thought to be insufficient to achieve long-term graft survival unless acceptable regimens are developed to reduce antibody responses. Soulillou (1998) *Xenotransplantation* 5:1-2.

Depleting the recipient of pathogenic anti- $\alpha$ Gal antibodies has been shown to prolong pig organ survival. Cooper et al. (1996) *Xenotransplantation* 4:27. However, attempts to remove the natural anti- $\alpha$ Gal antibodies by apheresis have been only temporarily effective and result in an only slightly delayed antibody-mediated organ rejection. Pathogenic levels of anti- $\alpha$ Gal antibodies return within 1-2 days and mediate xenograft damage. Sablinski et al. (1995) *Xenotransplantation* 2:264 ; Cooper et al. (1998) 10 *Xenotransplantation* 5:6. Thus, very frequent *ex vivo* plasmapheresis to reduce the incidence of HAR would be required. Furthermore, the cumulative damage by levels of anti- $\alpha$ Gal antibodies too low to mediate HAR but which mediate DXR are unavoidable using the plasmapheresis strategy. In addition, currently available pharmacological interventions, even in combination, only have modest effect in inhibiting anti- $\alpha$ Gal 15 antibody production. Cooper et al. (1998) *Xenotransplantation* 5:6. Thus, it seems unlikely that permanent suppression of anti- $\alpha$ Gal responses will be possible using this approach.

The use of mixed chimerism, wherein human organ recipients would be sublethally irradiated and reconstituted with autologous and porcine bone marrow, has been contemplated.  $\alpha$ Gal transferase knock out mice which do not express  $\alpha$ Gal have been tolerized via mixed hematopoietic chimerism. Thall et al. (1998) *J. Exp. Med.* However, instituting microchimerism of porcine marrow cells in primates would be problematic since primate marrow does not have the requisite species-specific hematopoietic cytokines/growth factors to facilitate their engraftment in the primate marrow.

Attempts to modify glycosylation of donor tissue, such as pig vascular endothelium have also been contemplated. However, pig knockouts (KO) created to effect the glycosylation modifications have not yet been accomplished due to a lack of porcine embryonic stem cells. Homologous recombination leading to the elimination of the  $\alpha$ 1,3 galactosyl transferase enzyme which leads to the expression of the  $\alpha$ Gal moiety has been accomplished in mice. Thall et al. (1995) *J. Biol. Chem.* 270:21437.  $\alpha$ Gal knock-out hearts still undergo rapid rejection when perfused with human plasma in *ex vivo* systems

indicating that decreasing  $\alpha$ Gal production may increase other xenoantigens such as the Forssman antigen. Tange et al. (1997) *Xenotransplantation* 4:20. In addition, extreme modifications of carbohydrate antigen expression on cell surfaces may have a detrimental effect on development and differentiation. Attempts to decrease  $\alpha$ Gal expression by making animals transgenic for a fucosyl transferase does not sufficiently decrease antigen expression. Galili et al. (1998) *Science and Medicine* 9:28. Thus, the general approach of modifying  $\alpha$ Gal expression, while theoretically appealing, may be untenable.

PCT application WO 98US2103 generally describes  $\alpha$ Gal compositions for inducing tolerance. French patent application FR 2751346 (based on WO 9803653) describes transgenic cells for transplantation which contain polynucleotides which encode antibodies directed against molecules involved in rejection. PCT application WO 9716064 describes transgenic cells which express a functional carbohydrate epitope modifying gene product which modifies a cell surface carbohydrate epitope such as  $\alpha$ Gal. See also PCT WO 950661 (nucleic acid sequences encoding  $\alpha$ 1,3-galactosyltransferase) and PCT WO 15 9421799 (nucleic acid sequences encoding  $\alpha$ 1,3-galactosyltransferase).

In sum, in humans and Old World primates, natural antibodies specific for the galactose  $\alpha$ 1,3 galactosyl ( $\alpha$ Gal) epitope mediate both the hyperacute rejection (HAR) and delayed xenograft rejection (DXR) of organs xenotransplanted from animals such as pigs. Anti- $\alpha$ Gal-mediated complement activation and endothelial cell activation induce an acute net procoagulant state on the endothelium of the engrafted organ leading to rapid clotting, ischemia and loss of organ function. Attempts to remove the natural anti- $\alpha$ Gal antibodies have been only temporarily effective and result in an only slightly delayed antibody-mediated organ rejection.

There is a serious need to develop compositions (such as toleragens) and methods that counteract the effect of circulating  $\alpha$ Gal antibodies in order to promote effectiveness of xenotransplantation.

All publications cited herein are hereby incorporated by reference in their entirety.

## SUMMARY OF THE INVENTION

We have discovered  $\alpha$ Gal conjugates with significantly increased ability to bind to anti- $\alpha$ Gal antibodies, including IgM antibodies, which are the major effector molecules of hyperacute rejection. The invention thus provides these conjugates, compositions comprising these conjugates, and methods using these conjugates.

5

Accordingly, in one aspect, the invention provides a conjugate comprising a valency platform molecule and an  $\alpha$ Gal epitope, wherein the valency platform molecule has a valency between two and 128. Preferred embodiments include valency platform molecules with a valency of two, four, six, eight, ten, twelve, sixteen, twenty, and twenty-five. The  $\alpha$ Gal epitope may be any moiety which specifically binds to an anti- $\alpha$ Gal antibody.

10

In another aspect, the invention provides a conjugate comprising a valency platform molecule and an  $\alpha$ Gal epitope, wherein the valency platform molecule has a valency of at least two, four, six, eight, ten, 12, 16, 20, and 25. The  $\alpha$ Gal epitope may be any moiety which specifically binds to an anti- $\alpha$ Gal antibody.

15

In another aspect, the invention provides compositions comprising the conjugates described herein, and preferably contain an effective amount of any of the conjugates described herein. In some embodiments, the compositions comprise a pharmaceutical excipient.

20

In another aspect, the invention provides methods of reducing circulating levels of anti- $\alpha$ Gal antibodies in an individual, comprising administering an effective amount any of the conjugates described herein to the individual, wherein an effective amount is an amount sufficient to reduce the circulating levels of anti- $\alpha$ Gal antibodies.

25

In another aspect, the invention provides methods of neutralizing circulating levels of anti- $\alpha$ Gal antibodies in an individual, comprising administering an effective amount of any of the conjugates described herein to the individual, wherein an effective amount is an amount sufficient to neutralize circulating levels of anti- $\alpha$ Gal antibodies.

30

In another aspect, the invention provides methods of inducing immunological tolerance (generally to a xenotransplantation antigen, more specifically to  $\alpha$ Gal), comprising administering an effective amount any of the conjugates described herein to the individual.

In another aspect, the invention provides methods of detecting the presence and/or amount of anti- $\alpha$ -Gal antibody in a biological sample comprising (a) contacting an  $\alpha$ -Gal conjugate of the invention with the biological sample under conditions that permit the formation of a stable antigen-antibody complex; and (b) detecting stable complex, if any, formed in step (a).

5 In another aspect, the invention provides methods for performing a xenotransplantation in an individual, comprising the steps of: (a) administering any of the conjugate(s) or composition(s) described herein to the individual; and (b) introducing xenotissue to an individual.

10 In another aspect, the invention provides methods of suppressing rejection of a transplanted tissue comprising an  $\alpha$ -Gal epitope in an individual, said method comprising administering any of the conjugates described herein to the individual in an amount sufficient to suppress rejection.

15

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a reaction scheme illustrating the enzymatic synthesis of the  $\alpha$ -Gal epitope, 2-[2-(2-thioethoxy) ethoxy]ethyl 3-O-( $\alpha$ -D-galactopyranosyl)- $\beta$ -D-galactopyranoside.

20 Figure 2 is a reaction scheme illustrating the chemical synthesis of the  $\alpha$ -Gal epitope, 2-[2-(2-thioethoxy) ethoxy]ethyl 3-O-( $\alpha$ -D-galactopyranosyl)- $\beta$ -D-galactopyranoside.

Figure 3 is a reaction scheme illustrating the chemoenzymatic synthesis of the  $\alpha$ -Gal epitope, *p*-aminophenyl 3-O- $\alpha$ -D-galactopyranosyl- $\alpha$ -D-galactopyranoside.

25 Figure 4 illustrates two general synthetic strategies for conjugation chemistry.

Figure 5 illustrates a third general synthetic strategy for conjugation chemistry.

Figure 6 illustrates two dimeric platforms (compounds 23 and 24) and four tetrameric platforms (compounds 25, 26, 27, and 28).

Figure 7 illustrates four octameric platforms (compounds 29, 30, 31, and 32).

30 Figure 8 illustrates a monomeric  $\alpha$ -Gal conjugate (compound 33) and four dimeric  $\alpha$ -Gal conjugates (compounds 33, 34, 35, and 36).

Figure 9 illustrates two tetrameric  $\alpha$ Gal conjugates (compounds 37 and 38) as described in Example 3.

Figure 10 illustrates three tetrameric  $\alpha$ Gal conjugates (compounds 39, 40, and 41) as described in Example 3.

5       Figure 11 illustrates two tetrameric conjugates (compounds 42 and 43) of two  $\alpha$ Gal-isomers as described in Example 3.

Figure 12 illustrates an octameric  $\alpha$ Gal conjugate (compound 44) as described in Example 3.

10      Figure 13 illustrates an octameric  $\alpha$ Gal conjugate (compound 45) as described in Example 3.

Figure 14 illustrates an octameric  $\alpha$ Gal conjugate (compound 46) as described in Example 3.

Figure 15 illustrates an octameric  $\alpha$ Gal conjugate (compound 47) as described in Example 3.

15      Figure 16 is a graph depicting the elution profile of anti- $\alpha$ Gal from an  $\alpha$ Gal affinity column (OD550 versus fraction number).

Figures 17A and 17B are graphs depicting affinity purified IgG (17A) and IgM (17B) anti- $\alpha$ Gal binding to PK15 cells. Flow cytometric analysis results are shown as mean fluorescence intensity (MFI) versus dose, in  $\mu$ g/ml, of affinity-purified IgG or IgM (solid circles), or column flow-through IgG or IgM (open squares).

20      Figure 18 is a graph depicting the effect of  $\alpha$ Gal valency of toleragens on inhibition of anti- $\alpha$ Gal binding, measured by ELISA as described in Example 4. Symbols for inhibitors are as follows: open circles =  $\alpha$ Gal monomer; open squares, dashed lines = LJP 724 (trisaccharide monomer); open squares, dashed lines = LJP 725 (pentasaccharide monomer); solid circles, solid lines =  $\alpha$ Gal dimer; solid squares, solid lines = LJP 712 tetramer; solid triangles, solid lines = LJP 719 octamer; open triangles, dashed lines = LJP 728 (11-mer pentasaccharide-BSA); solid triangles, dashed lines = LJP 726 (11-mer trisaccharide [3-carbon linker]-HSA); solid squares, dashed lines = LJP 727 (11-mer trisaccharide [14-carbon linker]-HSA).

Figure 19 is a bar graph of the percent plasma anti- $\alpha$ Gal IgG following treatment of primates with LJP 712, as described in Example 5.

Figure 20 is a graph depicting activation of the classical complement pathway by various substances, as described in Example 5. Symbols are as follows: open circles, LJP 712; open squares, cobra venom factor (CVF); solid triangles, aggregated human gamma globulin (AHG). The dashed line represents results obtained with buffer alone.

Figure 21 is a graph depicting activation of the alternative complement pathway by various substances, as described in Example 5. Symbols are as follows: open circles, LJP 712; open squares, CVF; solid triangles, AHG.

Figures 22A and 22B are graphs depicting the decrease in plasma anti- $\alpha$ Gal IgG (22A) and IgM (22B) following treatment with octameric LJP 920 (cpd 46) (circles), compared with PBS (squares), as described in Example 5.

Figure 23 is a graph comparing the effect of tetramer LJP 712 (open circles) with octamer LJP 920 (solid circles) on the percent plasma anti- $\alpha$ Gal IgM, as described in Example 5. PBS (solid squares) was included as a negative control.

Figure 24 depicts a strategy for the synthesis of octameric platform compound 29.

Figure 25 depicts a strategy for the synthesis of octameric platforms compounds 31 and 32.

Figures 26A and 26B depict the synthesis of octameric platform compound 30.

Figures 27A and 27B are graphs depicting the decrease in anti- $\alpha$ Gal IgM (27A) and IgG (27B) following treatment in GalT knock-out mice with octameric conjugate LJP 920 (diamonds), compared with PBS (squares), as described in Example 6.

Figures 28A and 28B are bar graphs depicting the decrease in spontaneous and rRBC-induced anti- $\alpha$ Gal IgM (28A) and IgG (28B) following treatment in GalT knock-out mice with octameric LJP 920 (left bar), compared with PBS (middle bar), as described in Example 6. Wild-type levels are shown in the right bar.

Figure 29 is a bar graph depicting the decrease in IgM anti- $\alpha$ Gal antibody forming cells in GalT knock-out mice treated with octameric LJP 920 compared with PBS as described in Example 6.

### MODES FOR CARRYING OUT THE INVENTION

We have discovered conjugates designed both to bind to and clear circulating anti- $\alpha$ Gal antibodies and bind to and tolerize  $\alpha$ Gal-specific B cells. The conjugates can be used to neutralize, reduce and/or remove anti- $\alpha$ Gal antibodies, whether transiently and/or more permanently (i.e., as a toleragen which dampens and/or eliminates the anti- $\alpha$ Gal antibody response in potential recipients of  $\alpha$ Gal epitope-bearing organs). They may also be used to detect circulating levels anti- $\alpha$ Gal antibodies. We have found that conjugates comprising a valency platform molecule and an  $\alpha$ Gal epitope can bind to and remove from the circulation the anti- $\alpha$ Gal IgG and IgM (the major effector molecule of hyperacute rejection) in a valency dependent manner that is consistent with the high affinity of the IgG anti- $\alpha$ Gal antibodies and the lower affinity but higher avidity of the IgM response.

#### *General Techniques*

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry and immunology, which are within the skill of the art. Such techniques are explained fully in the literature, such as, "Molecular Cloning: A Laboratory Manual", second edition (Sambrook et al., 1989); "Oligonucleotide Synthesis" (M.J. Gait, ed., 1984); "Animal Cell Culture" (R.I. Freshney), ed., 1987); "Methods in Enzymology" (Academic Press, Inc.); "Handbook of Experimental Immunology" (D.M. Weir & C.C. Blackwell, eds.); "Gene Transfer Vectors for Mammalian Cells" (J.M. Miller & M.P. Calos, eds., 1987); "Current Protocols in Molecular Biology" (F.M. Ausubel et al., eds., 1987); "PCR": The Polymerase Chain Reaction", (Mullis et al., eds., 1994); and "Current Protocols in Immunology" (J.E. Coligan et al., eds., 1991).

An " $\alpha$ Gal epitope" is any chemical moiety which exhibits specific binding to an anti- $\alpha$ Gal antibody. As such, examples of an  $\alpha$ Gal epitope include, but are not limited to, any moiety comprising a  $\alpha$ -D-galactopyranoside moiety, Gal, Gal $\alpha$ 1-3Gal, Gal $\alpha$ 1-4Gal, Gal $\alpha$ 1-6Gal, Gal $\alpha$ 1-3Gal $\alpha$ 1-3GlcNAc, Gal $\alpha$ 1-3Gal $\alpha$ 1-4Gal, Gal $\alpha$ 1-3Gal $\alpha$ 1-4GlcNAc,

Gal $\alpha$ 1-3Gal $\alpha$ 1-4Glc, Gal $\alpha$ 1-3Gal $\alpha$ 1-4[3-deoxy]GlcNAc, Gal $\alpha$ 1-3Gal $\alpha$ 1-4[6-deoxy]GlcNAc, Gal $\alpha$ 1-3Gal $\alpha$ 1-4Gal $\alpha$ 1-3Gal, Gal $\alpha$ 1-3Gal $\alpha$ 1-4GlcNAc $\alpha$ 1-3Gal $\alpha$ 1-4Glc, (McKane et al., *Transplantation* (1998) 66:626-633; Wieslander et al. *Glycoconjugate* (1990) 7:85-100; Galili et al. *J. Biol. Chem.* (1988) 263:17755-17762; Galili et al. *J. Exp. Med.* (1985) 162:573-582); peptides, and any multimers and combination(s) of the foregoing. Further discussion of  $\alpha$ Gal epitopes suitable for the conjugates of the invention are described below.

An epitope that "specifically binds" to an antibody is a term well understood in the art, and methods to determine such specific binding are also well known in the art. A molecule is said to exhibit "specific binding" if it reacts or associates more frequently, more rapidly, with greater duration and/or with greater affinity with a particular cell or substance than it does with alternative cells or substances. An antibody "specifically binds" to a target if it binds with greater affinity, avidity, more readily, and/or with greater duration than it binds to other substances. The term "epitope" also includes mimetics of  $\alpha$ Gal itself, which are described below,

As used in the specification and claims, and as this description makes clear to one skilled in the art, the singular form "a", "an", and "the" include plural references unless the context clearly indicates otherwise.

An "anti- $\alpha$ Gal antibody" or " $\alpha$ Gal antibody", used interchangeably herein, is any antibody which specifically binds to  $\alpha$ Gal. Any antibody includes an antibody of any class, such as IgG, IgA, or IgM, and the antibody need not be of any particular class. As clearly indicated in the definition of "antibody" provided herein, a "anti- $\alpha$ Gal antibody" encompasses any fragment(s) that exhibits this requisite functional (i.e., specific binding to  $\alpha$ Gal) property, such as fragments that contain the variable region, such as Fab fragments. As discussed below, it is understood that specific binding to any anti- $\alpha$ Gal antibody (or functional fragment) is sufficient.

An "antibody" (interchangeably used in plural form) is an immunoglobulin molecule capable of specific binding to a target, such as a carbohydrate or polypeptide, through at least one antigen recognition site, located in the variable region of the immunoglobulin molecule. As used herein, the term encompasses not only intact antibodies, but also fragments thereof (such as Fab, Fab', F(ab')<sub>2</sub>, Fv), single chain (ScFv),

mutants thereof, fusion proteins comprising an antibody portion, humanized antibodies, and any other modified configuration of the immunoglobulin molecule that comprises an antigen recognition site of the required specificity.

5       “Naturally occurring” refers to an endogenous chemical moiety, such as a carbohydrate, polynucleotide or polypeptide sequence, i.e., one found in nature. Processing of naturally occurring moieties can occur in one or more steps, and these terms encompass all stages of processing. Conversely, a “non-naturally occurring” moiety refers to all other moieties, i.e., ones which do not occur in nature, such as recombinant polynucleotide sequences and non-naturally occurring carbohydrates.

10      As used herein, the term “mimetic” (also termed an “analog”) means a biological or chemical compound which specifically binds to an anti- $\alpha$ Gal antibody. As such, for purposes of this invention, an “ $\alpha$ Gal epitope” includes mimetics of naturally-occurring  $\alpha$ Gal (such as peptides). A “mimetic” shares an epitope, or binding specificity, with  $\alpha$ Gal. A mimetic may be any chemical substance which exhibits the requisite binding properties, 15 and thus may be, for example, a simple or complex organic or inorganic molecule; a polypeptide; a polynucleotide; a carbohydrate; a lipid; a lipopolysaccharide; a lipoprotein, or any combination of the above, including, but not limited to, a polynucleotide-containing polypeptide; a glycosylated polypeptide; and a glycolipid. The term “mimetic” encompasses the term “mimotope”, which is a term well known in the art.

20      An “individual” is a vertebrate, preferably a mammal, more preferably a human. Mammals include, but are not limited to, farm animals, sport animals, pets, primates, mice and rats.

25      “Inducing tolerance” means a reduction and/or stabilization of the extent of an immune response to an immunogen. An “immune response” may be humoral and/or cellular, and may be measured using standard assays known in the art. For purposes of this invention, the immune response is generally reflected by the presence of anti- $\alpha$ Gal antibodies. Quantitatively the reduction (as measured by reduction in antibody production and/or levels) is at least about 15%, more preferably at least about 25%, more preferably at least about 50%, more preferably at least about 75%, more preferably at least about 90%, 30 even more preferably at least about 95%, and most preferably 100%. It is understood that the tolerance is antigen-specific, and applies for purposes of the invention to those

individuals having anti- $\alpha$ Gal antibodies. "Inducing tolerance" also includes slowing and/or delaying the rate of increase of antibody level.

An "effective amount" (when used in the toleragenic context) is an amount sufficient to effect beneficial or desired results, including clinical results. An effective amount can be administered in one or more administrations. For purposes of this invention, an effective amount of conjugate of this invention (or a composition comprising a conjugate of this invention) is an amount sufficient to reduce circulating levels of anti- $\alpha$ Gal antibodies, preferably (but not necessarily) by inducing tolerance, particularly with respect to anti- $\alpha$ Gal antibodies. In terms of treatment, an "effective amount" of conjugate of the invention (or a composition comprising a conjugate of the invention) is an amount sufficient to palliate, ameliorate, stabilize, reverse, slow or delay progression of or prevent rejection of  $\alpha$ Gal containing transplanted tissue. Detection and measurement of indicators of efficacy are generally based on measurement of  $\alpha$ Gal antibody and/or clinical symptoms associated with transplantation rejection.

In the case of hyperacute rejection, molecular changes subsequent to anti- $\alpha$ Gal binding to  $\alpha$ Gal-expressing blood vessels include complement activation and donor endothelial cell activation. This shifts the donor endothelium from an anti-coagulant environment into a procoagulant surface. This in turn leads to clotting in the vasculature of the engrafted organ and leads to an ischemic state in the organ. Thus, within minutes to 2 hours, blood flow to the organ ceases and the engrafted organ becomes black, with increasing hardness. If hyperacute rejection is avoided by antibody removal (pheresis) or complement regulation, antibodies produced subsequent to engraftment can lead to delayed xenograft rejection wherein antibodies bound to the endothelium of the engrafted organ can mediate graft cell activation, NK cell binding, antibody dependent cell-mediated cytotoxicity (ADCC) and increased immunogenicity of xenograft-specific antigens.

Accordingly, indications and/or clinical symptoms of transplantation rejection include, but are not limited to, reduction or loss of organ function (for example, change in urine output, for kidneys; and change in rhythm, for heart); complement activation, as indicated, for example, by presence or increased levels of components of the complement cascade, such as C3a, C5a, and C5b-9; NK activity; and antibody-dependent cell-mediated cytotoxicity (ADCC). For example, heart function may be monitored by measuring

appropriate markers, such as creatine kinase (CK), and CK isoenzyme CK MB, and lactate dehydrogenase in serum. Kidney failure is characterized by hematuria, decreased urine output, elevated blood urea nitrogen levels, elevated serum creatinine levels, hypertension, and proteinuria. Accordingly, these parameters can be monitored as a means of monitoring 5 kidney xenotransplant rejection.

As used herein "valency platform molecule" means a nonimmunogenic molecule containing sites which allow the attachment of a discrete number of epitopes and/or mimetic(s) of epitopes. A "valency" of a conjugate or valency platform molecule indicates the number of attachment sites per molecule for an  $\alpha$ Gal epitope(s). Alternatively, the 10 valency of a conjugate is the ratio (whether absolute or average) of  $\alpha$ Gal epitope to valency platform molecule.

"Nonimmunogenic", when used to describe the valency platform molecule, means that the valency platform molecule fails to elicit an immune response, and/or fails to elicit a sufficient immune response, when it is administered by itself to an individual. The degree 15 of acceptable immune response depends on the context in which the valency platform molecule is used, and may be empirically determined.

A "biological sample" encompasses a variety of sample types obtained from an individual and can be used in a diagnostic or monitoring assay. The definition encompasses blood and other liquid samples of biological origin, solid tissue samples such 20 as a biopsy specimen or tissue cultures or cells derived therefrom, and the progeny thereof. The definition also includes samples that have been manipulated in any way after their procurement, such as by treatment with reagents, solubilization, or enrichment for certain components, such as proteins or polynucleotides. The term "biological sample" encompasses a clinical sample, and also includes cells in culture, cell supernatants, cell 25 lysates, serum, plasma, biological fluid, and tissue samples.

A "stable complex" formed between any two or more components in a biochemical reaction, refers to a duplex or complex that is sufficiently long-lasting to persist between formation of the duplex or complex and subsequent detection, including any optional washing steps or other manipulation that may take place in the interim.

30 The term "neutralize", when used in the context of circulating anti- $\alpha$ Gal antibody, is a term well understood in the art and intends that an  $\alpha$ Gal conjugate of the invention binds

to a circulating anti- $\alpha$ Gal antibody such that it can no longer bind to an  $\alpha$ Gal epitope on donor tissue.

The term "circulating anti- $\alpha$ Gal antibody", as used herein, intends an anti- $\alpha$ Gal antibody which is not bound to an  $\alpha$ Gal antigen/epitope on donor tissue/organ, i.e., free antibody. "Levels" of circulating antibody means amount (quantity) of antibody.

"Reducing" levels of circulating anti- $\alpha$ Gal antibody means that the level of free, or unbound, circulating antibodies has been reduced. Levels of free antibody can be reduced by any of a number of ways, including binding a conjugate (so that the antibody can no longer be an effector molecule); clearance (removal from circulation); reduction of production via, for example, B cell anergy.

Conditions that "allow" or "permit" an event to occur, such as binding of an anti- $\alpha$ Gal antibody to an epitope which binds an anti- $\alpha$ Gal antibody, are conditions that do not prevent such events from occurring. Thus, these conditions enhance, facility, and/or are conducive to the event. Such conditions, known in the art and described herein, may be determined and practiced using standard methods in the art.

### *Conjugates of the invention*

The invention provides conjugates useful for prevention, reduction, and/or delay of xenotransplantation rejection based on undesirable immune response to  $\alpha$ Gal present on the transplanted tissue. The conjugates of the invention comprise (a) an  $\alpha$ Gal epitope; and (b) a valency platform molecule. Optionally, a linker is provided between the platform and the  $\alpha$ Gal epitope, as described below. Various valencies are permitted, and particularly preferred valencies are described below.

#### *$\alpha$ Gal epitope*

$\alpha$ Gal epitopes for use in the conjugates of the present invention may be any chemical moiety which specifically binds to an  $\alpha$ Gal antibody. As such, a conjugate which comprises an  $\alpha$ Gal epitope is a conjugate which contains any molecule or moiety which contains an  $\alpha$ Gal epitope.

Because the chemical structure of  $\alpha$ Gal is known, an the epitope is known ( $\alpha$ -D-galactopyranoside), one may prepare and obtain an  $\alpha$ Gal epitope from naturally-occurring  $\alpha$ Gal.

More preferably, an  $\alpha$ Gal epitope may also be made synthetically using standard chemical synthetic methods. Examples of synthetically produced  $\alpha$ Gal epitopes are provided in Example 1. Accordingly, examples of  $\alpha$ Gal epitopes used in the conjugates of the invention, include, but are not limited to, 2-[2-(2-thioethoxy)ethoxy]ethyl 3-O-( $\alpha$ -D-galactopyranosyl)- $\alpha$ -D-galactopyranoside; 2-[2-(2-thioethoxy)ethoxy]ethyl 6-O-( $\alpha$ -D-galactopyranosyl)- $\alpha$ -D-galactopyranoside; 2-[2-(2-Benzoylthioethoxy)ethoxy]ethyl  $\alpha$ -D-galactopyranoside; 2-[2-(2-tert-Butyldithioethoxy)ethoxy]ethyl  $\alpha$ -D-galactopyranoside; 2-[2-(2-tert-Butyldithioethoxy)ethoxy]ethyl 3-O-( $\alpha$ -D-galactopyranosyl)- $\alpha$ -D-galactopyranoside; 2-[2-(2-tert-butyldithioethoxy)ethoxy]ethyl 3-O-( $\alpha$ -D-galactopyranosyl)- $\alpha$ -D-galactopyranoside; *p*-aminophenyl-3-O-( $\alpha$ -D-galactopyranosyl)- $\alpha$ -D-galactopyranoside.

As made clear in the definition of an “ $\alpha$ Gal epitope”, an  $\alpha$ Gal epitope need not be based on, or derived from, the naturally-occurring a carbohydrate moiety, but may be, for example, a peptide. Examples of peptide  $\alpha$ Gal epitopes are provided in WO 97/11963. An  $\alpha$ Gal epitope may also be comprised of other organic moieties. For example, a series of organic compounds (whether randomly produced or non-randomly designed) may be synthesized and screened for the requisite binding activity.

Detection of specific binding may be conducted using standard techniques in the art, such as ELISA, FACS, and competition assays. Anti- $\alpha$ Gal antibodies may be isolated from a source of anti- $\alpha$ Gal antibodies, such as the serum of an immunized animal, using, for example, affinity chromatography. The Examples provide exemplary description of isolation of anti- $\alpha$ Gal antibodies and appropriate assays.

It is understood that, for purposes of this invention, more than one type of  $\alpha$ Gal epitope(s) may be used in preparing a conjugate. Alternatively, one type (i.e., one chemical species) of an  $\alpha$ Gal epitope may be used.

### Valency platform molecules

Any of a variety of non-immunogenic valency platform molecules (also called "platforms") may be used in the conjugates of the invention.

A platform may be proteinaceous or non-proteinaceous (i.e., organic). Examples of proteinaceous platforms include, but are not limited to, albumin, gammaglobulin, immunoglobulin (IgG) and ovalbumin. Borel et al. (1990) *Immunol. Methods* 126:159-168; Dumas et al. (1995) *Arch. Dermatol. Res.* 287:123-128; Borel et al. (1995) *Int. Arch. Allergy Immunol.* 107:264-267; Borel et al. (1996) *Ann. N.Y. Acad. Sci.* 778:80-87.

Preferably, the conjugates comprise a chemically defined valency platform molecule in which a precise valency (as opposed to an average) is provided. Certain classes of chemically defined valency platforms, methods for their preparation, conjugates comprising them, and methods for the preparation of such conjugates, have been described in the U.S. Patents Nos. 5,162,515; 5,391,785; 5,276,013; 5,786,512; 5,726,329; 5,268,454; 5,552,391; 5,606,047; and 5,663,395. Accordingly, a defined valency platform is a platform with defined structure, thus a defined number of attachment points and a defined valency. In contrast to previously described, more traditional platforms, these platforms have the advantage of having a homogeneous (i.e., uniform) molecular weight (as opposed to polydisperse molecular weight), and are thus "chemically defined". Accordingly, a population of conjugates using these platforms comprise a platform of homogeneous molecular weight or are substantially monodisperse (i.e., have a narrow molecular weight distribution). A measure of the breadth of distribution of molecular weight of a sample (such as a composition and/or population of platform molecules) of a platform molecule is the polydispersity of the sample. Polydispersity is used as a measure of the molecular weight homogeneity or nonhomogeneity of a polymer sample. Polydispersity is calculated by dividing the weight average molecular weight ( $M_w$ ) by the number average molecular weight ( $M_n$ ). The value of  $M_w/M_n$  is unity for a perfectly monodisperse polymer. Polydispersity ( $M_w/M_n$ ) is measured by methods available in the art, such as gel permeation chromatography. The polydispersity ( $M_w/M_n$ ) of a sample of platform molecules is preferably less than 2, more preferably, less than 1.5, or less than 1.2, less than 1.07, less than 1.02, or, e.g., about 1.05 to 1.5 or about 1.05 to 1.2. Typical polymers generally have a polydispersity of 2-5, or in some cases, 20 or more. Advantages of the

low polydispersity property of the valency platform molecules include improved biocompatibility and bioavailability since the molecules are substantially homogeneous in size, and variations in biological activity due to wide variations in molecular weight are minimized. The low polydispersity molecules thus are pharmaceutically optimally 5 formulated and easy to analyze. Further there is controlled valency of the population of molecules in the sample.

In some embodiments, the valency platform molecule comprises a carbamate linkage, i.e., -O-C(=O)-N<. Such platforms are described in a co-owned patent application entitled "Valency Platform Molecules Comprising Carbamate Linkages" U.S. 10 Serial No. 60/111,641. An example of such a platform is compound 30, which is shown in Figure 7. In other embodiments, the valency platform molecule comprises an aminoxy group, as described in co-owned U.S. Serial No. 60/138,260.

Preferred valency platform molecules are biologically stabilized, *i.e.*, they exhibit an *in vivo* excretion half-life often of hours to days to months to confer therapeutic efficacy, 15 and are preferably composed of a synthetic single chain of defined composition. They generally have a molecular weight in the range of about 200 to about 200,000, preferably about 200 to about 50,000 (or less, such as 30,000). Examples of valency platform 20 molecules within the present invention are polymers (or are comprised of polymers) such as polyethylene glycol (PEG), poly-D-lysine, polyvinyl alcohol, polyvinylpyrrolidone, D-glutamic acid and D-lysine (in a ratio of 3:2). Preferred polymers are based on polyethylene glycols (PEGs) having a molecular weight of about 200 to about 8,000. Other suitable platform molecules for use in the conjugates of the invention are albumin and IgG.

Other preferred valency platform molecules suitable for use within the present 25 invention are the chemically-defined, non-polymeric valency platform molecules disclosed in co-owned U.S. patent 5,552,391. Preferred homogeneous chemically-defined valency platform molecules suitable for use within the present invention are derivatized 2,2'-ethylenedioxydiethylamine (EDDA) and triethylene glycol (TEG).

Additional suitable valency platform molecules include, but are not limited to, 30 tetraaminobenzene, heptaaminobetacyclodextrin, tetraaminopentaerythritol, 1,4,8,11-tetraazacyclotetradecane (Cyclam) and 1,4,7,10-tetraazacyclododecane (Cyclen).


In general, these platforms are made by standard chemical synthesis techniques. PEG must be derivatized and made multivalent, which is accomplished using standard techniques. Some substances suitable for conjugate synthesis, such as PEG, albumin, and IgG are available commercially.

5       Synthesis of valency platforms, such as compound 25, 26, and 27, whose structures are shown in Figure 6, is described in co-owned patent application U.S. Serial No. 08/660,092 and co-owned International Patent Application Nos PCT/US96/09976 and PCT/US97/10075.

10      Synthesis of valency platforms 23, 24, 29, 30, 31 and 32, whose structures are shown in Figures 6 and 7, is described in Example 2.

As discussed above,  $\alpha$ Gal epitopes may be conjugated to any of a number of suitable platforms by any of a number of ways. In a preferred embodiment, the tetrabromoacetyl platform PIZ/IDA/TEG platform is used. Derivatives of the PIZ/IDA/TEG (PITG) platform can be prepared as shown below.

## Examples of Compatible Cross-linking Groups on PITG Platform



5

Platform	$\alpha$ Gal epitope	Conjugate
$R = XCH_2CO$	D1-SH	$R' = D1-SCH_2CO$

By way of example of a conjugate embodiment, an  $\alpha$ Gal epitope is prepared with a thiol linker at the N terminus by chemical or enzymatic synthesis (or by recombinant methods if the  $\alpha$ Gal epitope is a peptide). The linker can be cysteine or an SH containing moiety.

10 The modified epitope may then be alkylated by a suitably derivatized platform (such as bromoacetyl or iodoacetyl).

For purposes of this invention, the valency platform molecules have a minimum valency of at least two, preferably at least four, preferably at least six, more preferably at least eight, preferably at least 10, preferably at least 12. As an upper limit, valency is generally less than 128, preferably less than 64, preferably less than 35, preferably less than 30, preferably less than 25, preferably less than 24, preferably less than 20, although the upper limit may exceed 128. Without wishing to be bound by a particular theory, the valency is generally limited to numbers above which a conjugate could become a T cell independent antigen, i.e., would not induce B cell tolerance due to its T cell independence.

Thus, the invention includes conjugates with a valency of ranges of any of the lower limits of 2, 4, 6, 8, 10, 12, 16, with any of the upper limits of 128, 64, 35, 30, 25, 24, 20.

Preferably, the valency is at least eight (with the upper limits as described above). As described in the Examples, a synthetically prepared  $\alpha$ Gal epitope presented on a platform as an octamer inhibited both IgG and IgM anti- $\alpha$ Gal in serum from binding to BSA- $\alpha$ Gal or to the  $\alpha$ Gal-expressing porcine kidney epithelial cell line PK-15. By contrast, the tetrameric construct only removed the IgG. This difference may be attributed to the lower affinity of the IgM anti- $\alpha$ Gal antibodies which was overcome by increased epitope valency. This is significant, since IgM is the major effector molecule of HAR. By ELISA, there was no statistically significant diminution of anti- $\alpha$ Gal Ig responses with the tetramer at 2 - 10 mg/kg. By contrast, treatment with 20 mg/kg of the tetrameric conjugate (denoted "LJP 712", and also referred to as cpd 38 in the Examples) resulted in the diminution of the anti- $\alpha$ Gal IgG response by up to 24% ( $p<0.05$ ) and anti- $\alpha$ Gal IgM levels by up to 12% ( $p=NS$ ).

In some embodiments, the valency is two. In other embodiments, the valency is four. In other embodiments, the valency is eight. In other embodiments, the valency is 16. In other embodiments, the valency is any of the following: 6, 10, 14, 18, 20, 22, 24, 26, 28, 30, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 66, 68, 70, 72, 74, 76, 78, 80, 90, 120, 128. An example of a valency platform molecule with a valence of two is provided in Example 2 and Figure 6. An example of a valency platform molecule with a valence of four is provided in Example 2 and Figure 6. Examples of valency platform molecules with a valence of eight are provided in Example 2 and Figure 7. Accordingly, the invention includes conjugates comprising these valency platform molecules.

In other embodiments, valency platforms may be used which, when conjugated, provide an average valency (i.e., these platforms are not chemically defined in terms of their valency). Examples of such platforms are polymers such as linear PEG; branched PEG; star PEG; polyamino acids; polylysine; proteins; amino-functionalized soluble polymers.

#### *Conjugation of $\alpha$ Gal epitope(s) with valency platform molecules*

Conjugation of  $\alpha$ Gal epitope(s) with valency platform molecules is performed using standard chemical techniques. The following are examples of standard chemistry which

can be used: 1) thiol substitution; 2) thiol Michael addition; 3) amino alkylation; 4) disulfide bond formation. Figures 4 and 5 provide general, exemplary conjugation strategies.

Conjugation of an  $\alpha$ Gal epitope to a valency platform molecule may be effected in  
5 any number of ways, typically involving one or more crosslinking agents and functional groups on the epitope and valency platform molecule. Platforms and  $\alpha$ Gal epitope(s) must have appropriate linking groups. Linking groups are added to platforms using standard synthetic chemistry techniques. Linking groups may be added to an  $\alpha$ Gal epitope(s) using either standard solid phase synthetic techniques or recombinant techniques (if, for example,  
10 the  $\alpha$ Gal epitope is a peptide). Recombinant approaches may require post-translational modification in order to attach a linker, and such methods are known in the art.

As a further example, if the  $\alpha$ Gal epitope is a polypeptide, polypeptides contain  
15 amino acid side chain moieties containing functional groups such as amino, carboxyl, or sulfhydryl groups that serve as sites for coupling the polypeptide to the platform. Residues that have such functional groups may be added to the polypeptide if the polypeptide does not already contain these groups. Such residues may be incorporated by solid phase synthesis techniques or recombinant techniques, both of which are well known in the peptide synthesis arts. When the polypeptide has a carbohydrate side chain(s), functional  
20 amino, sulfhydryl and/or aldehyde groups may be incorporated therein by conventional chemistry. For instance, primary amino groups may be incorporated by reaction with ethylenediamine in the presence of sodium cyanoborohydride, sulfhydryls may be introduced by reaction of cysteamine dihydrochloride followed by reduction with a standard disulfide reducing agent, while aldehyde groups may be generated following periodate oxidation. In a similar fashion, the valency platform molecule may also be  
25 derivatized to contain functional groups if it does not already possess appropriate functional groups.

Hydrophilic linkers of variable lengths are useful for connecting  $\alpha$ Gal epitopes to valency platform molecules. Suitable linkers include linear oligomers or polymers of ethylene glycol. Such linkers include linkers with the formula

30  $R^1S(CH_2CH_2O)_nCH_2CH_2O(CH_2)_mCO_2R^2$  wherein n = 0-200, m = 1 or 2,  $R^1$  = H or a protecting group such as trityl,  $R^2$  = H or alkyl or aryl, e.g., 4-nitrophenyl ester. These

linkers are useful in connecting a molecule containing a thiol reactive group such as haloaceyl, maleiamide, etc., via a thioether to a second molecule which contains an amino group via an amide bond. These linkers are flexible with regard to the order of attachment, *i.e.*, the thioether can be formed first or last.

5        Particular conjugates are described in Example 3 and are depicted in Figures 8-15, which accordingly are provided as embodiments of the invention.

*Compositions of the invention*

The invention also provides compositions comprising any of the conjugates of the invention. Preferably, the compositions comprise an effective amount of a conjugate(s). An "effective amount" depends on the desired or intended result and may be determined empirically. For example, an amount effective to reduce circulating levels of anti- $\alpha$ Gal antibodies may be determined by conducting appropriate tests or studies. An amount effective to more permanently reduce the level of circulating anti- $\alpha$ Gal antibodies (*i.e.*, induce tolerance) may likewise be determined empirically.

With respect to compositions which may be used as reagents (such as in detection of anti- $\alpha$ Gal antibodies), these compositions generally comprise an amount of an  $\alpha$ Gal conjugate of the invention sufficient to effect detection. These amounts are readily determined empirically. These compositions may further comprise a substance, such as a buffer, to effect detection and/or to allow formation of a stable complex between an anti- $\alpha$ Gal antibody and an  $\alpha$ Gal epitope on a conjugate of the invention. These compositions may also optionally be complexed to a detection matrix, such as a solid phase (*e.g.*, in an immunoaffinity column).

In some embodiments, the compositions comprise a conjugate(s) and a pharmaceutically acceptable excipient, and may be in various formulations.

Pharmaceutically acceptable excipients are known in the art, and are relatively inert substances that facilitate administration of a pharmacologically effective substance. For example, an excipient can give form or consistency, or act as a diluent. Suitable excipients include but are not limited to stabilizing agents, wetting and emulsifying agents, salts for varying osmolarity, encapsulating agents, buffers, and skin penetration enhancers.

Excipients as well as formulations for parenteral and nonparenteral drug delivery are set forth in *Remington's Pharmaceutical Sciences* 19th Ed. Mack Publishing (1995).

Generally, these compositions are formulated for administration by injection (e.g., intraperitoneally, intravenously, subcutaneously, intramuscularly, etc.). Accordingly, these compositions are preferably combined with pharmaceutically acceptable vehicles such as saline, Ringer's solution, dextrose solution, and the like. Generally, the conjugate will normally constitute about 0.01% to 10% by weight of the formulation due to practical, empirical considerations such as solubility and osmolarity. The particular dosage regimen, i.e., dose, timing and repetition, will depend on the particular individual and that individual's medical history. Generally, a dose of about 1 µg to about 100 mg conjugate/kg body weight, preferably about 100 µg to about 10 mg/kg body weight, preferably about 50 µg to about 5 mg/kg body weight, preferably about 1 µg to about 1 g conjugate/kg body weight, preferably about 5 µg to about 500 mg body weight. Empirical considerations, such as the half life, generally will contribute to determination of the dosage. If used as a toleragen, conjugate may be administered daily, for example, in order to effect antibody clearance (pheresis), followed by less frequent administrations, such as two times per week, once a week, or even less frequently. Frequency of administration may be determined and adjusted over the course of therapy, and is based on maintaining tolerance (i.e., reduced or lack of immune response to αGal). Other appropriate dosing schedules may be as frequent as daily or 3 doses per week, or one dose per week, or one dose every two to four weeks, or one dose on a monthly or less frequent schedule depending on the individual or the disease state. Repetitive administrations, normally timed according to B cell turnover rates, may be required to achieve and/or maintain a state of humoral anergy. Such repetitive administrations generally involve treatments of about 1 µg to about 10 mg/kg body weight or higher every 30 to 60 days, or sooner, if an increase in anti-αGal antibody level is detected. Alternatively, sustained continuous release formulations of the compositions may be appropriate. Various formulations and devices for achieving sustained release are known in the art.

Other formulations include suitable delivery forms known in the art including, but not limited to, carriers such as liposomes. Mahato et al. (1997) *Pharm. Res.* 14:853-859.

Liposomal preparations include, but are not limited to, cytofectins, multilamellar vesicles and unilamellar vesicles.

In some embodiments, more than one conjugate (e.g., mixtures that vary with respect to valency and/or nature of epitope) may be present in a composition. Such compositions may contain at least one, at least two, at least three, at least four, at least five different conjugates. Such "cocktails", as they are often denoted in the art, may be particularly useful in treating a broader range of population of individuals. They may also be useful in being more effective than using only one (or fewer than are contained in the cocktail) conjugate(s).

The compositions may be administered alone or in conjunction with other forms of agents that serve to enhance and/or complement the effectiveness of a conjugate of the invention, including, but not limited to, anti-helper T cell treatments. Such treatments usually employ agents that suppress T cells such as steroids or cyclosporin. The compositions may also be administered with agents (such as immunosuppressants) which are used to suppress transplantation rejection.

An individual suitable for administration of a conjugate(s) (or composition comprising an conjugate(s) of the invention) is one who has or will receive tissue which is known to contain (i.e., expressed on the cell surface), or is believed to contain,  $\alpha$ Gal. In order to tolerize an individual to a donor organ or tissue, it is generally preferable to administer the conjugate before transplantation, generally at least about 1 to about 5, preferably at least about 5 to about 10, more preferably at least about 10 to about 30, even more preferably at least about 30 to about 60 days before transplantation. In order to neutralize circulating anti- $\alpha$ Gal Ab, e.g., in an acute setting, the conjugate can be administered either concurrently with or after xenotransplantation. Accordingly, depending on the desired result, the conjugate can be administered before, during, or after transplantation. Preferably, the individual is human. Measurable circulating levels of anti- $\alpha$ Gal antibody need not be detectable, as mounting an immune response after transplantation could occur.

*Kits comprising conjugates*

The invention also provides kits containing (i.e., comprising) one or more conjugates of the invention. The kits may be used, for example, as vehicles for administration of the conjugate(s) contained therein in a clinical setting. The kits of this 5 invention are in suitable packaging, and may optionally provide additional components such as, buffers and instructions (which may pertain to administration and/or detection). Because the conjugates of the invention may be used to detect anti- $\alpha$ Gal antibody, kits of the invention may additionally or alternatively contain reagents suitable for detection of anti- $\alpha$ Gal antibody, such as capture reagents, developing reagents, labels, reacting surfaces, 10 means for detection, control samples, and interpretive information.

Any appropriate means for detecting binding of the antibodies may be employed (and provided in the kits) such as a labeled anti-human antibody, when the presence of human anti- $\alpha$ Gal antibodies is tested, wherein the label may be an enzyme, fluorophore, chemiluminescent material radioisotope or coenzyme. Generally, the label used will be an 15 enzyme.

*Methods using the conjugates of the invention*

The invention provides methods of using conjugate(s) of this invention. The conjugates can be used to reduce circulating levels of anti- $\alpha$ Gal antibody; induce 20 immunological tolerance in an individual to  $\alpha$ Gal epitopes on donor tissue/organs; to neutralize circulating anti- $\alpha$ Gal antibodies in an individual; to detect the presence and/or amount of anti- $\alpha$ Gal Ab in a biological sample; and can also be used in a method of performing a xenotransplantation in an individual. Reduction of circulating levels of anti- $\alpha$ Gal antibody can be accomplished, using  $\alpha$ Gal conjugates of the invention, by inducing 25 immunological tolerance to  $\alpha$ Gal and/or by neutralizing anti- $\alpha$ Gal antibody. Neutralizing anti- $\alpha$ Gal antibody can be achieved *in vivo* or *ex vivo*. With respect to all of these methods, the conjugate(s) (or composition comprising the conjugate(s)) may be used alone or in conjunction with other agents which promote the desired activity/objective. Various formulations and means of administration have been discussed above.

*Inducing immunological tolerance in an individual*

The invention provides methods of inducing tolerance in an individual comprising administering an effective amount of any of the conjugate(s) (or compositions comprising the conjugate(s)) described herein. It is understood that, for purposes of this invention, that the immune response to be reduced (and/or eliminated, stabilized, and or rate of increase reduced), via inducing tolerance, is an immune response to  $\alpha$ Gal. Accordingly, the tolerance induced is antigen specific, wherein the antigen is  $\alpha$ Gal.

Determination of whether tolerance has been induced may be achieved by any means known in the art. In general, tolerance is determined by measuring the immune response, which can be measured using standard assays, including, for example, measuring serum levels of anti- $\alpha$ Gal antibody; measuring anti- $\alpha$ Gal Ab-producing B cells by ELISpot assay; measuring cytokine production following immunization with  $\alpha$ Gal (or  $\alpha$ Gal conjugate); performing *in vitro* analyses of T-cell response to  $\alpha$ Gal (or  $\alpha$ Gal epitope) after administration of  $\alpha$ Gal or conjugates thereof using T cells from the individual receiving such administration, including, for example, standard assays such as  $^3$ H-thymidine uptake to measure proliferation of T cells when presented with  $\alpha$ Gal (or  $\alpha$ Gal epitope) in the context of an antigen-presenting cell, standard  $^{51}$ Cr release assays to measure killing by cytotoxic T cells of a cell presenting  $\alpha$ Gal (or  $\alpha$ Gal epitope), and the like.

Immunological tolerance in B cells toward  $\alpha$ Gal can occur, for example, by anergy, or as a result of apoptosis. Regardless of the mechanism, B cell tolerance results in a reduction in, or loss of, the ability of B cells to produce, express on their surface and/or secrete anti- $\alpha$ Gal antibody. To determine whether a reduction or loss of the ability of B cells to produce, express on their surface and/or secrete anti- $\alpha$ Gal Ab, B cells can be obtained from, for example a primary or secondary lymphoid organ such as spleen or lymph node, or blood, and production of anti- $\alpha$ Gal antibody measured. If the anti- $\alpha$ Gal antibody is secreted, it can be measured by an immunoassay such as ELISA, using, for example an immobilized  $\alpha$ Gal conjugate of the invention, and detecting bound anti- $\alpha$ Gal antibody using an appropriate labelled second antibody, such as an anti-isotype antibody. Anti- $\alpha$ Gal antibody present on the surface of a B cell can be measured by FACS, using labelled anti-human IgM antibody or, alternatively, labelled  $\alpha$ Gal conjugate.

*Reducing circulating anti- $\alpha$ Gal antibodies in an individual*

The invention further provides methods of reducing circulating levels of anti- $\alpha$ Gal antibody in an individual, comprising administering an effective amount (i.e., an amount sufficient to reduce antibody levels) of any of the conjugate(s) (or compositions comprising the conjugate(s)) described herein.

Determination of reduction of circulating levels of  $\alpha$ Gal antibodies may be achieved using standard assays in the art, such as ELISA. Preferably, the reduction (as compared to an earlier measured level) is at least about any of the following: 10%, 20%, 30%, 40%, 50%. The extent of reduction desired will depend on a number of factors, including, but not limited to, condition of the individual; whether other agent(s) are or will be used; nature of the transplant tissue.

*Reducing levels of anti- $\alpha$ Gal antibody in fluids ex vivo*

In some embodiments, reduction of levels of circulating anti- $\alpha$ Gal antibody is performed *ex vivo*. Accordingly, this invention provides methods for reducing levels of anti- $\alpha$ Gal antibodies in a biological fluid of an individual, comprising contacting the fluid with an  $\alpha$ Gal conjugate of the invention *ex vivo* under conditions that permit the antibodies to bind epitopes on the platform. Suitable bodily fluids include those that can be returned to the individual, such as blood, plasma, or lymph.

Affinity adsorption apheresis is described generally in Nilsson et al. (1981) *Blood* 58(1):38-44; Christie et al. (1993) *Transfusion* 33:234-242; Richter et al. (1997) *ASAIO J.* 43(1):53-59; Suzuki et al. (1994) *Autoimmunity* 19: 105-112; U.S. Patent No. 5,733,254; Richter et al. (1993) *Metabol. Clin. Exp.* 42:888-894; Richter et al. (1997) *ASAIO J.* 43(1):53-59; and Wallukat et al. (1996) *Int'l J. Card.* 54:191-195. Any of these methods can be used.

In the methods of the invention, the bodily fluid is removed from the individual for extracorporeal binding to an  $\alpha$ Gal conjugate of this invention comprising epitopes reactive with anti- $\alpha$ Gal antibody. For example, apparatuses and methods for removing blood and separating it into its constituent components are known in the art (see, e.g., U.S. Patent Nos. 4,086,924; 4,223,672). The blood or portions thereof are then exposed to an  $\alpha$ Gal conjugate. The  $\alpha$ Gal conjugate neutralizes anti- $\alpha$ Gal antibody, and the blood components are then optionally returned to the individual.

In a preferred technique, the anti- $\alpha$ Gal- $\alpha$ Gal conjugate complex is removed before the fluid is returned to the individual. This may be done, for example, by using a carrier attached to a solid phase, or by using a soluble carrier and selectively removing the complex from the treated solution.

To create a solid phase, an  $\alpha$ Gal conjugate can be adapted to render it insoluble. For example, where  $\alpha$ Gal conjugate comprises one of the platforms listed above, then the platform can be chemically adapted during synthesis to include an additional reactive group in the core structure. For example, an additional linkage can be added to a triethylene glycol structure present in the core. The linkage is then used to attach the platform to an insoluble structure, such as a polystyrene or polyethylene bead, a polycellulose membrane, or other desirable structure. Commercially available matrices include agarose (a neutral linear polysaccharide generally composed of D-galactose and altered 3,6-anhydrogalactose residues, for example Sepharose™, Pharmacia), activated gels, nitrocellulose, borosilicate, glass fiber filters, silica, polyvinylchloride, polystyrene, and diazotized paper. Methods for preparing peptide-peptide conjugates are described in Hermanson, G.T., "Bioconjugate Techniques", Academic Press: New York, 1996; and in "Chemistry of Protein Conjugation and Cross-linking" by S.S. Wong, CRC Press, 1993. The biological fluid to be treated is simply treated with the solid phase, and antibodies in the fluid complex to the solid phase. The supernatant fluid can then be removed from the solid phase for return to the individual. In some instances, the solid phase can also be cleared of antibody for repeat use by using a suitable wash, providing both the epitope and the carrier is resistant to the washing solution. Suitable washing solutions may include 0.1 M glycine buffer, pH 2.4, dilute acetic acid, or 1 M KSCN buffered to ~pH 7.

If the  $\alpha$ Gal conjugate is not part of a solid phase, then the antibody- $\alpha$ Gal conjugate complex can be removed from the fluid by any other appropriate method, including but not limited to microfiltration, antibody capture, or precipitation. Solutions suitable to cause precipitation of the complex depend on the solubility of the complex, and may include ammonium sulfate or polyethylene glycol. If the fluid is to be returned to the individual, then the precipitating solution should be chosen so that any that remains in the fluid does not cause an adverse reaction in the individual. Methods of returning blood to the individual are well-known in the art. Two processes commonly used are continuous and

discontinuous processes. The continuous process involves removing the blood of an individual in a steady flow, separating the plasma from the cellular components, treating the plasma, recombining the plasma with the cellular component and then reinfusing the individual. The discontinuous process involves removing a small volume of blood,  
5 separating the plasma from the cellular components of that particular volume, treating the plasma of that volume, reconstituting the two components and reinfusing the volume into the individual.

This disclosure contemplates devices which can be used for reducing the level of anti- $\alpha$ Gal antibody in a biological fluid using an  $\alpha$ Gal conjugate of this invention.  
10 Typically, the device will be a flow system, comprising the following elements: a) a port that permits biological fluid to flow into the device; b) a chamber in which the fluid is permitted to contact the  $\alpha$ Gal conjugate (optionally in a solid phase); c) a port that permits the treated fluid to flow out of the device. Such devices can be designed as continuous flow systems, and as systems that permit the treatment of a single sample from an  
15 individual for purposes of analysis or readministration at a subsequent time.

#### *Neutralizing anti- $\alpha$ Gal antibodies*

The invention also provides methods of neutralizing circulating levels of anti- $\alpha$ Gal antibodies in an individual, comprising administering an effective amount of any of the conjugates described herein to the individual, wherein an effective amount is an amount sufficient to neutralize circulating levels of anti- $\alpha$ Gal antibodies. Not all circulating anti- $\alpha$ Gal antibodies need be neutralized. Methods of detecting binding of conjugate to circulating anti- $\alpha$ Gal antibodies may be performed using methods standard in the art and described below. For example, a blood sample may be obtained from an individual who has received a conjugate described herein, and levels of anti- $\alpha$ Gal antibodies (as detected  
20 by using the same epitope as used on the conjugate) may be compared to initial level of anti- $\alpha$ Gal antibodies (i.e., before administration). A lowering of levels indicates that anti- $\alpha$ Gal antibodies are being neutralized. Because neutralization should occur relatively quickly upon administration of conjugate, such measurements are preferably taken within 1 day, preferably within about 12 hours, more preferably within about 10 hours, more preferably  
25 within about 8 hours, more preferably within about 4 hours of administration of conjugate.  
30

*Detecting presence and/or amount of anti- $\alpha$ Gal antibody*

The invention further provides methods for detecting the presence of and/or quantitating the amount of anti- $\alpha$ Gal antibody in a biological sample comprising (a) contacting an  $\alpha$ Gal conjugate of the invention with the biological sample under conditions that permit the formation of a stable antigen-antibody complex; and (b) detecting stable complex, if any, formed in step (a). Current detection methods employ  $\alpha$ Gal epitopes coupled to a protein carrier, so that the epitope recognized by any given antibody could also include the  $\alpha$ Gal epitope plus one or more amino acids, the identity of which could vary widely, depending upon where the linkage to the protein carrier occurred. In addition, the valency of such  $\alpha$ Gal-protein conjugates is highly variable. The conjugates of the present invention, in contrast, are defined, both in terms of structure and valency, and thus confer a major advantage in a diagnostic assay, such as an ELISA, in that one would be detecting only anti- $\alpha$ Gal Ab, and standard curves generated with  $\alpha$ Gal conjugates of the invention would be more uniform, i.e., less subject to lot-to-lot variation.

In one embodiment, the invention provides methods of detecting an antibody that specifically binds to an  $\alpha$ Gal epitope(s) in a biological sample. These methods are generally applicable in the clinical setting, for example, for diagnosing and/or monitoring anti- $\alpha$ Gal antibody levels in an individual. These methods entail contacting (anti- $\alpha$ Gal) antibody in the sample with an  $\alpha$ Gal conjugate (i.e., any conjugate of this invention) under conditions suitable to allow the formation of a stable complex between anti- $\alpha$ Gal antibody (such as an anti- $\alpha$ Gal antibody reactive with donor tissue/organ) and an  $\alpha$ Gal epitope(s), and detecting a stable complex formed, if any. The  $\alpha$ Gal conjugates of the invention render these methods particularly useful, as no generally convenient or suitable assay for these antibodies has yet been developed. A number of immunoassay methods are known in the art and need not be described in detail.

An anti- $\alpha$ Gal antibody may be expressed on the surface of a B cell. Accordingly, in another embodiment, the invention provides methods of detecting a B cell expressing an anti- $\alpha$ Gal antibody on its surface. These methods entail contacting (anti- $\alpha$ Gal) antibody-expressing B cells in a biological sample with an  $\alpha$ Gal conjugate (i.e., any conjugate of this invention) under conditions suitable to allow the formation of a stable complex between

anti- $\alpha$ Gal antibody (such as an anti- $\alpha$ Gal antibody reactive with donor tissue/organ) and an  $\alpha$ Gal epitope(s), and detecting a stable complex formed, if any.

Suitable samples in which to measure  $\alpha$ Gal antibody are biological samples, including serum or plasma (preferably serum) and donor tissue eluate. For detection of 5 anti- $\alpha$ Gal antibody-expressing B cells, suitable samples include whole blood, which has preferably been treated to remove red blood cells. It is well understood in the art that detection of a complex formed may be direct (such as by measuring the amount of label associated with a complex) or indirect (such as in measuring the amount of labeled ligand which is displaced during the assay).

To use an  $\alpha$ Gal conjugate of this invention in the detection of such antibodies in an 10 individual, an immunoassay is conducted. The  $\alpha$ Gal conjugate is provided as a reagent, and the anti- $\alpha$ Gal antibody is the target in the biological sample. For example, human IgG antibody molecules present in a serum sample may be captured with solid-phase protein A, and then overlaid with the labeled polypeptide reagent. The amount of antibody would 15 then be proportional to the label attached to the solid phase. Alternatively, cells or tissue sections expressing  $\alpha$ Gal may be overlaid first with the test sample containing the antibody, and then with a detecting reagent such as labeled anti-immunoglobulin. The amount of antibody would then be proportional to the label attached to the cells. The amount of antibody detected in the sample would be compared with the amount detected in a control 20 sample.

To detect anti- $\alpha$ Gal antibody-expressing B cells, after formation of a stable complex between a B cell and a suitably labeled  $\alpha$ Gal conjugate of the invention, the complex can be detected by, for example, fluorescence activated cell sorting (FACS) analysis. Suitable 25 sources of B cells include, but are not limited to, blood, or a secondary lymphoid organ such as spleen or lymph node.

In the methods of the invention, an  $\alpha$ Gal conjugate will typically be immobilized, by known techniques, onto a suitable solid phase, such as affinity column packing material, or a plastic surface such as a microtiter plate or a dipstick. Appropriate affinity column packing materials include, for example, a beaded agarose matrix, polyacrylamide, glass, cellulose or cross-linked dextran. Suitable plastic surfaces include polymethacrylate, 30 polystyrene, polyethylene, polyterephthalate, ethylene glycol, polyester, polypropylene, and

the like. Generally, any standard microtiter plate may be used. Alternatively, the solid phase may be in the form of a gel or matrix into which the  $\alpha$ Gal conjugate is incorporated.

For further illustration, a test sample potentially containing an antibody that specifically binds to an  $\alpha$ Gal epitope(s) can be mixed with a pre-determined non-limiting amount of the  $\alpha$ Gal conjugate which is generally detectably labeled (such as with a radioisotope or enzyme). In a liquid phase assay, unreacted reagents are removed by a separation technique, such as filtration or chromatography. In these immunoassay techniques, the amount of label associated with the complex positively correlates with the amount of anti- $\alpha$ Gal antibody present in the sample. Similar assays can be designed in which anti- $\alpha$ Gal antibody in the test sample compete with labeled antibody for binding to a limiting amount of the  $\alpha$ Gal conjugate. Here, the amount of label negatively correlates with the amount of anti- $\alpha$ Gal antibody in the sample.

In some embodiments, the biological sample is a tissue sample, or a tissue eluate, and the amount of anti- $\alpha$ Gal antibody associated with the tissue sample is measured by, for example, a competitive binding assay. These methods may be especially useful in those contexts in which a particular tissue should be tested and/or monitored for presence and/or amount of anti- $\alpha$ Gal antibody. This type of assay may indicate, for example, whether a particular disease (or risk of disease) may be indicated (such as a particular form of thrombosis or clotting disorder). Such an assay may also be useful in providing more precise and sensitive determination of localization of anti- $\alpha$ Gal antibody for diagnostic and/or monitoring purposes. Further, localization information about anti- $\alpha$ Gal antibody may also provide a clinician with indication about suitable treatment options.

It is understood that these detection methods are applicable in a variety of clinical contexts. For instance, detection may be used to identify individuals who show risk of developing anti- $\alpha$ Gal antibody-associated conditions or disorders, such as xenoplant rejection, which may in turn arise from being unable to distinguish antibodies associated with pathology and those not associated with pathology. Detection may also be used to monitor treatment (such as administration of any of the compositions described above). Detection may also assist in distinguishing between pathogenic antibodies from non-pathogenic antibodies. Detection may also assist the clinician in deciding the best treatment options and/or prognosis.

*Performing xenotransplantation*

The invention also provides methods of performing a xenotransplantation in an individual, comprising (a) introduction of  $\alpha$ Gal-bearing tissue to the individual; and (b) administering an effective amount of any of the conjugate(s) (or compositions comprising the conjugate(s) described herein) to the individual. Methods of transplantation, such as surgical transplantation, are known in the art and need not be described herein. Any  $\alpha$ Gal-bearing tissue (i.e., tissue which contains, or is believed to contain,  $\alpha$ Gal on at least part of its surface (i.e., surface cells of the tissue)) may be used, including, but not limited to, kidney; liver; pancreas; lung; heart; lung-heart block transplants; cells, including, but not limited to, insulin-producing cells of the pancreas, and fetal neural cells (e.g., dopamine-producing brain cells for treating Parkinson's disease). The source of these tissues may vary, and generally are from pig. Administration of conjugates and compositions has been discussed above. Preferably, the conjugate(s) is administered to the individual prior to introduction of  $\alpha$ Gal-bearing tissue. Accordingly, the transplantation methods of the invention also include administering a conjugate described herein at least about any of the following prior to introduction of tissue: 5 days, 10 days, 15 days, 20 days, 30 days, 45 days, 50 days, 60 days. The relationship between administration of conjugate and introduction of  $\alpha$ Gal-bearing tissue will depend on several factors, including but not limited to, the conjugate used, the tissue introduced, and/or the individual's condition (including medical history).

As is understood by one skilled in the art, an  $\alpha$ Gal-bearing tissue includes  $\alpha$ Gal-bearing cells, and, as such, the xenotransplantation methods of the invention include administration of  $\alpha$ Gal-bearing cells.

The invention also includes methods of suppressing rejection of a transplanted  $\alpha$ Gal-bearing tissue in an individual, comprising administering any of the conjugates described herein to the individual in an amount sufficient to suppress rejection. Indicia of rejection have been discussed herein. "Suppressing" rejection means any one or more of the following states: slowing, delaying, stopping rejection. "Suppressing" rejection indicates an extent of rejection that is reduced or curtailed compared to the extent of rejection without administering the conjugate, i.e., that the extent of rejection at a given time point is reduced when compared to otherwise same conditions except for receiving the

conjugate. Preferably, the conjugate is compound 46 (LJP 920). Administration, formulations, and  $\alpha$ Gal bearing tissues have been discussed above, including the discussion of transplantation methods. Conjugate may be administered before and/or after the individual receives the  $\alpha$ Gal bearing tissue. The dosage may vary depending, inter alia, on whether a conjugate is used in conjunction with another agent(s) designed to suppress rejection, such as an immunosuppressant.

5 The following examples are provided to illustrate but not limit the present invention.

10

## EXAMPLES

### Example 1: Synthesis of $\alpha$ Gal epitopes

The general analytical methods and characterization techniques used in the present disclosure are identified below. NMR spectra were recorded on a Bruker AC300 spectrometer at 300 MHz for  $^1\text{H}$  and 75 MHz for  $^{13}\text{C}$ . Chemical shifts were recorded in parts per million ( $\delta$ ) relative to TMS (i.e., tetramethylsilane,  $\delta = 0.0$  ppm) or to the residual signal of deuterated solvents: chloroform ( $\delta = 7.27$  ppm for  $^1\text{H}$ ;  $\delta = 77.23$  ppm for  $^{13}\text{C}$ ), methanol ( $\delta = 4.87$  ppm for  $^1\text{H}$ ;  $\delta = 49.15$  ppm for  $^{13}\text{C}$ ) and  $\text{D}_2\text{O}$  ( $\delta = 4.80$  (DSS) ppm for  $^1\text{H}$ ). Coupling constants ( $J$ ) are reported in hertz. Analytical HPLC analyses were performed on a Hewlett Packard liquid chromatography HP 1090 instrument fitted with a Vydac C18 column (4.6 x 250 mm, 5  $\mu\text{m}$  particle size). Preparative HPLC was performed on Dynamax SD 200 system with Vydac C18 column (22 x 250 mm, 10  $\mu\text{m}$  particle size). Mass spectra were recorded on Finnigan LCQ mass spectrometer.

25

Enzymatic synthesis of the  $\alpha$ Gal epitope, 2-[2-(2-thioethoxy)ethoxy]ethyl 3-O-( $\alpha$ -D-galactopyranosyl)- $\beta$ -D-galactopyranoside: A reaction scheme illustrating the synthesis is shown in Figure 1.

Compound 2

S-2-[2-(2-Hydroxylethoxy)ethoxy]ethyl thiobenzoate

To a mixture of 2-[2-(2-chloroethoxy)ethoxy]ethanol, compound 1 (20 g, 0.12 mol) and thiobenzoic acid (16.4 g, 0.12 mol) was added 12 g of triethylamine at room temperature. The mixture was then stirred at 90°C for 1 h. After cooled to room temperature, ethyl acetate (100 mL) was added to the reaction mixture and filtered. The filtrate was concentrated and purified via silica gel chromatography (hexane/ethyl acetate, 1:1) to give compound 2 (30.6 g, 95%) as an orange syrup:  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  7.97 (dd,  $J$  = 8.3, 1.4, 2 H), 7.56 (d,  $J$  = 7.4, 1 H), 7.45 (t,  $J$  = 6.9, 2 H), 3.73 (m, 4 H), 3.68 (s, 4 H), 3.62 (m, 2 H), 3.31 (t, 2 H).

Compound 4

2-[2-(2-Benzoylthioethoxy)ethoxy]ethyl 2,3,4,6-tetra-O-acetyl- $\beta$ -D-galactopyranoside

To a solution of compound 2 (7.79 g, 28.9 mmol) and acetobromo- $\alpha$ -D-galactose, compound 3 (17.80 g, 43.28 mmol) in dry  $\text{CH}_2\text{Cl}_2$  (100 mL) were added  $\text{Ag}_2\text{CO}_3$  (9.27 g, 36.1 mmol) and activated 4Å molecular sieve (powder, 10 g) at 0 °C. After stirred at room temperature for 3 d, the reaction mixture was filtered through Celite and the filtrate was concentrated and purified via silica gel chromatography (hexane/ethyl acetate, 4:1) to give compound 4 (12.29 g, 71%) as a colorless syrup:  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  7.99-7.95 (m, 2 H), 7.61-7.55 (m, 1 H), 7.48-7.43 (m, 2 H), 5.39 (dd,  $J$  = 1.0, 3.4, 1 H), 5.21 (dd,  $J$  = 7.9, 10.5, 1 H), 5.03 (dd,  $J$  = 3.4, 10.5, 1 H), 4.58 (d,  $J$  = 7.9, 1 H), 4.14 (dd,  $J$  = 2.9, 6.9, 1 H), 3.99-3.89 (m, 2 H), 3.79-3.65 (m, 10 H), 3.30 (t,  $J$  = 6.4, 2 H), 2.15-1.98 (4s, 12 H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  191.4, 170.3, 170.2, 170.0, 169.4, 136.9, 133.4, 128.5, 127.2, 101.3, 97.4, 70.9, 70.6, 70.5, 70.3, 69.8, 69.0, 68.8, 67.0, 61.2, 20.7, 20.6, 20.5; MS (ESI): m/e (M + Na $^+$ ) Calcd. for  $\text{C}_{27}\text{H}_{36}\text{O}_{13}\text{SNa}$ : 623.2, obsd.: 623.2.

Compound 62-[2-(2-tert-Butyldithioethoxy)ethoxy]ethyl  $\beta$ -D-galactopyranoside

To a stirred solution of compound 4 (3.47 g, 5.77 mmol) in methanol (15 mL) was added NaOCH<sub>3</sub> (0.50 g, 9.28 mmol) at 0 °C. After 3 h, diethyl 1-(*tert*-butylthio)-1,2-hydrzainedicarboxylate, compound 5 (2.2 g, 8.3 mmol), which was prepared as described (Wunsch, E., et al. *Hoppe-Seyler's Z. Physiol. Chem.* 1982, 363, 1461-1464), was added. The reaction mixture was stirred at room temperature for another 2 h. Dowex 50X2-400 resin was then added to neutralized the solution and filtered. The filtrate was concentrated and purified via silica gel chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 9:1) to give compound 6 (1.22 g, 51%) as a white solid: <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 4.39 (br s, 1 H), 4.35 (br d, 2 H), 4.11 (br s, 1 H), 4.02 (br s, 2 H), 3.84 (br s, 2 H), 3.78-3.48 (m, 13 H), 2.89 (t, J = 6.7, 2 H), 1.33 (s, 9H); MS (ESI): m/e (M + 1) Calcd. for C<sub>16</sub>H<sub>33</sub>O<sub>8</sub>S<sub>2</sub>: 417.2, obsd.: 417.5.

Compounds 7 and 82-[2-(2-tert-Butyldithioethoxy)ethoxy]ethyl 3-O-( $\alpha$ -D-galactopyranosyl)- $\beta$ -D-galactopyranoside(7)2-[2-(2-tert-butylthioethoxy)ethoxy]ethyl 3-O-( $\alpha$ -D-galactopyranosyl)- $\beta$ -D-galactopyranoside (8):

To a solution of compound 6 (2.87 g, 6.89 mmol) and *p*-nitrophenyl  $\alpha$ -D-galactopyranoside (200 mg) in 10 mL of sodium phosphate buffer (50 mM, pH 6.5) was added 20 mg of coffee bean  $\alpha$ -galactosidase. The reaction was proceeded at room temperature with gradual addition of donor until 300 mM *p*-nitrophenol had been formed (3 d). The reaction mixture was lyophilized and the residue was suspended in methanol, filtered and concentrated. The unreacted starting material (2.5 g) was recovered by silica gel chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 95:5 to 70:30). The products were first purified on P2 Gel filtration column eluted with water and then on reverse phase HPLC column to yield compound 7 (80 mg, 2.0%) and compound 8 (106 mg, 2.6%) as white solids. For compound 7: analytical RF-HPLC: t<sub>R</sub> 8.49 min with a gradient of 25 to 30% ACN in H<sub>2</sub>O at a flow rate of 1 mL/min, purity, 100%; <sup>1</sup>H NMR (CD<sub>3</sub>OD): 5.04 (d, J = 1.9, 1 H), 4.32

(dd,  $J = 1.6, 6.2, 1$  H), 4.25 (t,  $J = 5.5, 1$  H), 4.05-4.00 (m, 2 H), 3.93 (d,  $J = 1.2, 1$  H), 3.83-3.61 (m, 17 H), 3.52 (t, 1 H), 2.89 (t,  $J = 6.6, 2$  H), 1.33 (s, 9H); MS (ESI): m/e (M + Na<sup>+</sup>) Calcd. for C<sub>22</sub>H<sub>42</sub>O<sub>13</sub>S<sub>2</sub>Na: 601.2, obsd.: 601.2. For compound 8: analytical RF-HPLC: t<sub>R</sub> 7.14 min with a gradient of 25 to 30% ACN in H<sub>2</sub>O at a flow rate of 1 mL/min, purity, 100%; <sup>1</sup>H NMR (CD<sub>3</sub>OD): 4.27(d,  $J = 7.5, 1$  H), 4.00-3.62 (m, 22 H), 3.50 (m, 1 H), 2.89 (t,  $J = 6.6, 2$  H), 1.36 (s, 9 H); MS (ESI): m/e (M + Na<sup>+</sup>) Calcd. for C<sub>22</sub>H<sub>42</sub>O<sub>13</sub>S<sub>2</sub>Na: 601.2, obsd.: 601.1.

These two disaccharides were further characterized after acetylated with Ac<sub>2</sub>O in pyridine at room temperature overnight: for acetylated compound 7: <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 5.46 (br d,  $J = 3.3, 1$  H), 5.37 (br d,  $J = 3.3, 1$  H), 5.31-5.22 (m, 3 H), 5.14 (dd,  $J = 3.3, 10.2, 1$  H), 4.50 (d,  $J = 7.8, 1$  H), 4.29 (br t,  $J = 6.5, 7.3, 1$  H), 4.21 (dd,  $J = 7.3, 11.3, 1$  H), 4.14 (d,  $J = 7.3, 2$  H), 4.04 (dd,  $J = 6.5, 10.8, 1$  H), 3.91 (dd,  $J = 10.4, 2.9, 1$  H), 3.84 (br t,  $J = 7.3, 1$  H), 3.87-3.62 (m, 10 H), 2.91 (t,  $J = 7.6, 2$  H), 2.15-1.95 (7s, 21 H), 1.35 (s, 9 H) and for acetylated compound 8: <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 5.42 (br d,  $J = 3.1, 1$  H), 5.41 (br d,  $J = 3.0, 1$  H), 5.28 (dd,  $J = 3.0, 10.4, 1$  H), 5.19 (dd,  $J = 7.8, 10.4, 1$  H), 5.12 (dd,  $J = 3.3, 10.4, 1$  H), 5.02 (dd,  $J = 3.1, 10.4, 1$  H), 4.93 (d,  $J = 3.3, 1$  H), 4.57 (d,  $J = 7.8, 1$  H), 4.21 (br t,  $J = 6.8, 1$  H), 4.09 (m, 2 H), 3.95 (dt,  $J = 3.9, 10.8, 1$  H), 3.86 (br t,  $J = 6.6, 1$  H), 3.81-3.62 (m, 10 H), 3.44 (dd,  $J = 7.4, 10.2, 1$  H), 2.89 (t,  $J = 6.7, 2$  H), 2.12-1.98 (7s, 21 H), 1.35 (s, 9 H).

20

Chemical synthesis of the αGal epitope, 2-[2-(2-thioethoxy)ethoxy]ethyl 3-O-(α-D-galactopyranosyl)-β-D-galactopyranoside: A reaction scheme illustrating this synthesis is shown in Figure 2.

25

### Compound 10

2-[2-(2-chloroethoxy)ethoxy]ethyl 2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside

To a mixture of galactose pentaacetate, compound 9 (70 g, 179 mmol), 2-[2-(2-chloroethoxy)ethoxy]ethanol (45.4 g, 270 mmol) and activated 4Å molecular sieve (20 g) 30 in dry CH<sub>2</sub>Cl<sub>2</sub> (500 mL) was added BF<sub>3</sub>Et<sub>2</sub>O (52 g, 370 mmol) dropwise at room temperature for 3 h. After stirred for 2 d, the suspension was filtered through Celite and the

filtrate was poured into 300 mL of saturated aqueous NaHCO<sub>3</sub> cooled in an ice bath. The organic phase was separated and the aqueous phase was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic phases were washed with brine, dried, and concentrated. The residue was purified via silica gel chromatography (hexane/ethyl acetate, 1:1) to give compound 10 (67g, 75%) as a colorless oil: <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 5.36 (d, J = 3.2, 1 H), 5.19 (dd, J = 10.4, 8.0, 1 H), 5.00 (dd, J = 10.4, 3.6, 1 H), 4.55 (d, J = 8.0, 1 H), 4.18-4.08 (m, 3 H), 3.91-3.87 (m, 2 H), 3.74 (m, 2H), 3.72-3.61 (m, 8 H), 2.13 (s, 3 H), 2.04 (s, 3 H), 2.03 (s, 3 H), 1.96 (s, 3 H).

10

Compound 11

2-[2-(2-chloroethoxy)ethoxy]ethyl  $\beta$ -D-galactopyranoside

A solution of compound 10 (67g, 134 mmol) in 200 mL of methanol and 250 mL of 1 M K<sub>2</sub>CO<sub>3</sub> aqueous solution was stirred at room temperature overnight. The reaction mixture was poured into 700 mL of methanol cooled with ice-water bath. The precipitate was filtered through celite and washed with methanol. The filtrate was combined and neutralized with Dowex resin (H form) until pH 6. The resin was filtered and washed with water. The filtrate was concentrated and lyophilized to give compound 11 (37 g, 83%) as a colorless oil: <sup>1</sup>H NMR (D<sub>2</sub>O): δ 4.30 (d, J = 7.2, 1 H), 3.95 (m, 1 H), 3.80 (d, J = 3.6, 1 H), 3.80-3.50 (m, 15 H), 3.40 (m, 1 H).

Compound 12

2-[2-(2-chloroethoxy)ethoxy]ethyl 3-O-p-methoxybenzyl- $\beta$ -D-galactopyranoside

A mixture of compound 11 (37 g, 112 mmol) and dibutyltin oxide (46 g, 210 mmol) in dry MeOH (300 mL) was refluxed under nitrogen until clear (10 hr). The reaction mixture was concentrated and the residue was dried under vacuum. The residue was dissolved in 800 mL of dioxane and 80 mL of DMF and p-methoxybenzyl chloride (32 g, 28 ml, 0.20 mol) was added. The resulting mixture was stirred at 100 °C for 10 h to give a brownish solution with precipitate. After cooled to room temperature, the precipitate was removed by filtration through Celite and washed with dioxane (100 mL) and chloroform

(100 mL). The combined organic phases were concentrated and purified by silica gel chromatography (ethyl acetate) to give compound 12 (30 g, 60%) as a colorless oil.

Compound 13

5           2-[2-(2-chloroethoxy)ethoxy]ethyl 2,4,6-tri-O-acetyl-3-O-p-methoxybenzyl  $\beta$ -D-galactopyranoside

10          Compound 12 (30 g, 66.5 mmol) was acetylated with Ac<sub>2</sub>O (150 mL) in pyridine (150 mL), catalyzed by DMAP (120 mg). After stirred for 5 h, the reaction mixture was concentrated. The residue was dissolved in chloroform (300 mL) and washed with HCl solution (0.5 M), water, saturated aqueous NaHCO<sub>3</sub> and brine. The organic phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated to give compound 13 (34 g, 89%) as a colorless oil: <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  7.19 (d, *J* = 8.6, 2 H), 6.87 (d, *J* = 8.6, 2 H), 5.48 (d, *J* = 3.3, 1 H), 5.10 (dd, *J* = 10.0, 8.1, 1 H), 4.62 (d, *J* = 11.6, 1 H), 4.45 (d, *J* = 8.1, 1 H), 4.34 (d, *J* = 11.6, 1 H), 4.17 (dd, *J* = 6.7, 1.0, 2 H), 3.94 (m, 1 H), 3.82-3.61 (m, 15 H), 3.49 (dd, *J* = 10.0, 3.3, 1 H), 2.16 (s, 3 H), 2.08 (s, 3 H), 2.04 (s, 3 H); MS (ESI): m/e (M + Na<sup>+</sup>) Calcd. for C<sub>26</sub>H<sub>37</sub>ClO<sub>12</sub>Na: 599.2, obsd: 599.4.

Compound 14

20          2-[2-(2-chloroethoxy)ethoxy]ethyl 2,4,6-tri-O-acetyl  $\beta$ -D-galactopyranoside

25          To a solution of compound 13 (34 g, 59 mmol) in 300 mL of CH<sub>3</sub>CN/water (9:1) was added CAN (64 g, 120 mmol) slowly during 3 h at 0 °C. After addition, the mixture was stirred at the same temperature for 3 h. The reaction mixture was then concentrated, diluted with 250 mL of water, and extracted with chloroform. The organic extracts were washed with saturated aqueous NaHCO<sub>3</sub> and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue was purified via flash column chromatography (hexane/ethyl acetate, 3:1 to 2:3) to give compound 14 (20.4 g, 76%) as a colorless oil: <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  5.31 (d, *J* = 3.6, 1 H), 4.95 (dd, *J* = 10.0, 7.8, 1 H), 4.51 (d, *J* = 8.0, 1 H), 4.13 (m, 2 H), 3.94 (m, 1 H), 4.00-3.61 (m, 14 H), 2.15 (s, 3 H), 2.11 (s, 3 H), 2.04 (s, 3 H).

Compound 16

2-[2-(2-chloroethoxy)ethoxy]ethyl 3-O-(2,3,4,6-tetra-O-benzyl- $\alpha$ -D-galactopyranosyl)-2,4,6-tri-O-acetyl- $\beta$ -D-galactopyranoside

5 To a mixture of compound 14 (10 g, 22 mmol), compound 15 (25.4 g, 45 mmol), 4-methyl-2,6-di-*t*-butyl pyridine (6.8 g, 33 mmol), and activated 4 $\text{\AA}$  molecular sieve (10 g) in dry ether (300 mL) was added a solution of methyl triflate (7.2 mL) in ether (50 mL) dropwise via a syringe-pump over a period of 24 h. After stirred at room temperature for 36 h, the reaction mixture was filtered through Celite. The filtrate was concentrated and purified via silica gel chromatography (hexane/ethyl acetate, 4:1 to 1:1) to give compound 16 (17.3 g, 81%) as a yellowish oil:  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  7.35-7.22 (m, 20 H), 5.43 (d,  $J$  = 3.2, 1 H), 5.16 (dd,  $J$  = 10.0, 8.0, 1 H), 5.06 (d,  $J$  = 3.4, 1 H), 4.90 (d,  $J$  = 11.6, 1 H), 4.81 (d,  $J$  = 12.0, 1 H), 4.68-4.62 (m, 3 H), 4.46-4.39 (m, 4 H), 4.12-3.59 (m, 20 H), 3.49 (d,  $J$  = 6.4, 2 H), 2.03 (s, 3 H), 1.94 (s, 3 H), 1.79 (s, 3 H); MS (ESI): m/e (M + Na $^+$ ) Calcd. for 10  $\text{C}_{52}\text{H}_{63}\text{ClO}_{16}\text{Na}$ : 1001.4, obsd: 1001.8.

15

Compound 17

2-[2-(2-chloroethoxy)ethoxy]ethyl 3-O- $\alpha$ -D-galactopyranosyl-2,4,6-tri-O-acetyl- $\beta$ -D-galactopyranoside

20 A mixture of compound 16 (18.1 g, 18.5 mmol) and Pd/C (20%, 3 g) in 300 mL of methanol and 1.5 mL of acetic acid was shaken under compressed hydrogen (50 psi) at room temperature for 9 h. The reaction mixture was filtered through Celite and concentrated. Water (10 mL) was added to the residue to assist the removal of acetic acid 25 and the crude product was used directly in next reaction without purification.  $^1\text{H}$  NMR ( $\text{CD}_3\text{OD}$ ):  $\delta$  5.52 (dd,  $J$  = 10.0, 8.4, 1 H), 4.98 (d,  $J$  = 3.6, 1 H), 4.62 (d,  $J$  = 8.0, 1 H), 4.14 (m, 2 H), 4.06 (m, 1 H), 3.98 (t,  $J$  = 8.4, 1 H), 3.92 (m, 1 H), 3.86 (d,  $J$  = 2.7, 1 H), 3.77-3.61 (m, 16 H), 3.55 (dd,  $J$  = 10.0, 3.2, 1 H), 2.13 (s, 3 H), 2.11 (s, 3 H), 2.03 (s, 3 H). MS (ESI): m/e (M + Na $^+$ ) Calcd. for  $\text{C}_{24}\text{H}_{39}\text{ClO}_{16}\text{Na}$ : 641.2, obsd: 641.3.

25

30

Compound 18

2-[2-(2-chloroethoxy)ethoxy]ethyl 3-O- $\alpha$ -D-galactopyranosyl- $\beta$ -D-galactopyranoside

5 A solution of compound 17 in 40 mL of 1M NaOH and 300 mL of methanol was stirred at room temperature for 6 h. The reaction mixture was neutralized with Dowex resin (H form) to pH 6, filtered and lyophilized to give compound 18 (8.9 g, 97%) as a white solid.  $^1$ H NMR ( $D_2O$ ):  $\delta$  5.18 (d,  $J$  = 3.7, 1 H), 4.53 (d,  $J$  = 7.7, 1 H), 4.25-3.68 (m, 24 H). MS (ESI): m/e (M + Na $^+$ ) Calcd. for  $C_{18}H_{33}ClO_{13}Na$ : 515.2, obsd: 515.5.

10

Compound 19

2-[2-(2-acetylthioethoxy)ethoxy]ethyl 3-O-( $\alpha$ -D-galactopyranosyl)- $\beta$ -D-galactopyranoside

15 A solution of compound 18 (8.9 g, 18.1 mmol) in 100 mL of 1 M potassium thioacetate was stirred at 95 °C under nitrogen for 36 h. The reaction mixture was cooled and loaded on a column packed with Dowex ion exchange resin (H form, 100 g) and eluted with water. The aqueous solution was neutralized with Dowex Marathon WBA anion exchange resin (from pH 2 to 5), filtered, and lyophilized to give compound 19 (7.5 g, 20 78%) as an off-white solid.  $^1$ H NMR ( $D_2O$ ):  $\delta$  5.17 (d,  $J$  = 3.8, 1 H), 4.52 (d,  $J$  = 7.7 Hz, 1 H), 4.24-3.67 (m, 25 H), 3.15 (t,  $J$  = 6.2, 2 H); MS (ESI): m/e (M + Na $^+$ ) Calcd. for  $C_{20}H_{36}O_{14}SNa$ : 555.2, obsd: 555.3.

Compound 20

25 2-[2-(2-thioethoxy)ethoxy]ethyl 3-O-( $\alpha$ -D-galactopyranosyl)- $\beta$ -D-galactopyranoside

30 A mixture of compound 19 (650, 1.22 mmol) and 4 g of DOWEX 550A OH anion-exchange resin, pre-washed with methanol, in 50 mL of methanol was stirred at room temperature overnight. The reaction mixture was filtered and the resin was washed with 5% acetic acid in methanol. The filtrate was concentrated to give compound 20 (578 mg, 97%)

as a white solid:  $^1\text{H}$  NMR ( $\text{CD}_3\text{OD}$ ):  $\delta$  5.00 (d,  $J = 3.6$ , 1 H), 4.35 (d,  $J = 7.6$  Hz, 1 H), 4.04 (m, 2H), 3.93 (m, 1 H), 3.84 (m, 1 H), 3.82 (dd,  $J = 10.4$ , 3.2, 1 H), 3.73-3.51 (m, 18 H), 2.83 (t,  $J = 6.0$ , 2 H);  $^{13}\text{C}$  NMR ( $\text{D}_2\text{O}$ ):  $\delta$  103.2, 95.8, 77.8, 75.4, 72.7, 71.4, 70.2, 70.1, 69.9, 69.7, 69.2, 68.9, 68.7, 65.4, 61.5, 37.9, 23.5; MS (ESI): m/e (M + Na $^+$ ) Calcd. for 5  $\text{C}_{18}\text{H}_{34}\text{O}_{13}\text{SNa}$ : 513.5, obsd: 513.3.

The synthetically prepared  $\alpha$ Gal epitope on resin was antigenically active as demonstrated by its ability to remove >95% of anti- $\alpha$ Gal Ig from normal rhesus monkey or human serum, as measured by FACS.

10

### Compound 22

p-aminophenyl 3-O- $\alpha$ -D-galactopyranosyl- $\alpha$ -D-galactopyranoside

A reaction scheme illustrating the chemoenzymatic synthesis of the  $\alpha$ Gal epitope, p-aminophenyl 3-O- $\alpha$ -D-galactopyranosyl- $\alpha$ -D-galactopyranoside (22) is shown in Figure 15 3. *p*-Nitrophenyl 3-O- $\alpha$ -D-galactopyranosyl- $\alpha$ -D-galactopyranoside (compound 21) was prepared enzymatically as described by Nilsson (Tetrahedron Lett. (1997) 38:133-136). A mixture of *p*-nitrophenyl 3-O- $\alpha$ -galactopyranosyl- $\alpha$ -D-galactopyranoside (70 mg, 0.15 mmol) and 10 mg Pd/C (10%) in methanol (4 mL) was stirred under hydrogen at room 20 temperature overnight. The reaction mixture was then filtered through Celite and the filtrate was concentrated in vacuo to give (50 mg) as a yellowish solid:  $^1\text{H}$  NMR ( $\text{CD}_3\text{OD}$ ):  $\delta$  6.87 (t, 2 H), 6.57 (d, 2 H), 5.21 (d, 1 H), 4.98 (d, 1 H), 4.2-4.1 (m, 2 H), 4.1-3.8 (m, 3 H), 3.8-3.7 (m, 3 H), 3.7-3.5 (m, 4 H);  $^{13}\text{C}$  NMR ( $\text{CD}_3\text{OD}$ ):  $\delta$  143.8, 120.1, 117.9, 115.4, 101.2, 97.6, 78.3, 77.0, 72.6, 71.5, 71.4, 70.3, 68.7, 67.4, 63.2, 62.6; MS (ESI): m/e (M + Na $^+$ ) 25 Calcd. for  $\text{C}_{18}\text{H}_{27}\text{NO}_{11}\text{Na}$ : 456.2, obsd: 456.2.

### Example 2: Synthesis of valency platforms

#### Synthesis of Compound 23

30 A solution of 1,4-diaminobutane and  $\text{NaHCO}_3$  in water/dioxane 1/1 is treated with bromoacetic anhydride. The mixture is extracted with  $\text{CH}_2\text{Cl}_2$ , and the  $\text{CH}_2\text{Cl}_2$  layer is

dried and concentrated to give crude product which is purified by silica gel chromatography to give compound 23.

#### Synthesis of Compound 24

5 A solution of 4,7,10-trioxa-1,3-tridecanediamine and NaHCO<sub>3</sub> in water/dioxane 1/1 is treated with bromoacetic anhydride. The mixture is extracted with CH<sub>2</sub>Cl<sub>2</sub>, and the CH<sub>2</sub>Cl<sub>2</sub> layer is dried and concentrated to give crude product which is purified by silica gel chromatography to give compound 24.

#### Synthesis of Compound 29

A strategy for synthesis of compound 29 is shown in Figure 24.

Compound A: A solution of 1,3-diamino-2-hydroxypropane in aqueous dioxane was treated with di-t-butylcarbonate and Na<sub>2</sub>CO<sub>3</sub>. The mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub>, and the CH<sub>2</sub>Cl<sub>2</sub> layer was dried and concentrated to give crude product which was purified by silica gel chromatography to give compound B.

15 Compound B was treated with p-toluenesulfonyl chloride in pyridine. The mixture was acidified with aqueous HCl and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The CH<sub>2</sub>Cl<sub>2</sub> layer was dried and concentrated to give crude product which was purified by silica gel chromatography to give compound C.

20 A solution of compound C in a suitable solvent is treated with thiobenzoic acid and a suitable base. The mixture is extracted with CH<sub>2</sub>Cl<sub>2</sub>, and the CH<sub>2</sub>Cl<sub>2</sub> layer is dried and concentrated to give crude product which is purified by silica gel chromatography to give compound D.

25 A solution of compound D in MeOH is treated with one equivalent of NaOH until the thiobenzoate ester is hydrolyzed as evidenced by TLC. To the resulting mixture is added 0.25 equivalents of compound 26. The mixture is stirred until complete as evidenced by TLC. The mixture is acidified with aqueous H<sub>2</sub>SO<sub>4</sub> and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The CH<sub>2</sub>Cl<sub>2</sub> layer is dried and concentrated to give crude product which is purified by silica gel chromatography to give compound E.

Compound E is treated with trifluoroacetic acid to remove the BOC protecting groups. The mixture is concentrated, and the residue is dissolved in a solution of NaHCO<sub>3</sub> in 1/1 dioxane/water. To the resulting solution is added eight equivalents of bromoacetic anhydride. The mixture is stirred until complete as evidenced by TLC. The mixture is acidified with aqueous H<sub>2</sub>SO<sub>4</sub> and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The CH<sub>2</sub>Cl<sub>2</sub> layer is dried and concentrated to give crude product which is purified by silica gel chromatography to give compound 29.

#### Synthesis of Compound 30

A chemical scheme for the preparation of an octamer of HEGA/TEG is shown in Figures 26A and 26B. Compound 30. The bis-hexaethyleneglycolamine (compound 4') was reacted with di-tert-butyl dicarbonate to yield the N-BOC compound (compound 8'), which was then reacted with *para*-nitrophenylchloroformate to yield the *para*-nitrophenylcarbonate compound (compound 9'). The *para*-nitrophenylcarbonate (PNP) group was then converted to a carbamate group by reaction with mono-CBZ-protected piperazine, yielding compound 10'. The BOC group was removed using trifluoroacetic acid to yield compound 11'. Compounds 9' and 11' were then reacted together to form a “one-sided” dendritic compound (compound 12'). Again, the BOC group was removed using trifluoroacetic acid to yield compound 13'. Compound 13' was then reacted with triethyleneglycol bis chloroformate (from which the “core” is derived) to yield the “two-sided” dendritic compound (compound 14'). The terminal CBZ-protected amino groups were then converted to the hydrobromide salt of amino group, and further reacted with bromoacetic anhydride to yield reactive bromoacetyl groups at each of the termini in compound 30.

25

#### Synthesis of Compounds 31 and 32

A strategy for synthesis of compound 31 and 32 is shown in Figure 25.

Tetraamino platform, compound F, was reacted with the N-hydroxysuccinimidyl ester of N<sub>α</sub>,N<sub>ε</sub>-bis-CBZ-lysine in a solution of water/acetonitrile which contained Na<sub>2</sub>CO<sub>3</sub>.

The acetonitrile was removed under vacuum, and the product precipitated. The precipitate was washed with water and recrystallized from acetonitrile to give G.

5 The CBZ groups were removed from compound G by catalytic hydrogenation using 10% Pd on carbon in ethanol. The mixture was filtered, and the filtrate was concentrated to give the octa-amine, compound H, as a brown oil.

Compound H was reacted with chloroacetic anhydride in methanol/acetonitrile at room temperature overnight. The crude product was purified by silica gel chromatography to give compound 31.

10

### Compound 32

A solution of compound H is reacted with acryloyl chloride or acrylic anhydride in the presence of suitable base. The solvent is removed, and the crude product is purified by silica gel chromatography to give compound 32.

15

### Example 3: Synthesis of $\alpha$ Gal conjugates

#### Compound 33

##### Synthesis of monomeric $\alpha$ Gal Conjugate

20

A mixture of  $\alpha$ Gal 20 (100 mg, 0.204 mmol), chloroacetamide (38 mg, 0.408 mmol), and tributylphosphine (10  $\mu$ L) in 1 mL of  $\text{Na}_2\text{CO}_3$  (10 mg/mL) solution in water/ACN (1:1) was stirred at room temperature overnight. After removing the organic solvent, the remaining aqueous solution was purified on reversed phase HPLC column eluted at 10 mL/min with a gradient of acetonitrile-water (5 to 15%) over 40 minutes to give 33 (96.3 mg, 86%) as a white solid: analytical RF-HPLC:  $t_R$  4.78 min with a gradient of 5 to 20% ACN in  $\text{H}_2\text{O}$  at a flow rate of 1 mL/min. purity, 100%; MS (ESI): m/e (M + Na $^+$ ) Calcd. for  $\text{C}_{20}\text{H}_{37}\text{NO}_{14}\text{SNa}$ : 570.2, obsd: 570.3.

Compound 34Synthesis of dimeric  $\alpha$ Gal Conjugate

A mixture of  $\alpha$ Gal 20 (65 mg, 0.133 mmol) in 1 mL of  $\text{Na}_2\text{CO}_3$  (20 mg/mL) aqueous solution was stirred at room temperature overnight. The solution was purified on reversed phase HPLC column eluted at 10 mL/min with a gradient of acetonitrile-water (10 to 25%) over 40 minutes to give 34 (31.3 mg, 48%) as a white solid: analytical RF-HPLC:  $t_R$  9.96 min with a gradient of 5 to 30% ACN in  $\text{H}_2\text{O}$  at a flow rate of 1 mL/min. purity, 100%; MS (ESI): m/e ( $M + \text{Na}^+$ ) Calcd. for  $\text{C}_{36}\text{H}_{66}\text{NO}_{26}\text{S}_2\text{Na}$ : 1001.3, obsd: 1001.3.

10

Compound 35Synthesis of Dimeric  $\alpha$ Gal Conjugate

A mixture of  $\alpha$ Gal 19 (30 mg, 0.056 mmol), dimeric platform 23 (9.3 mg, 0.028 mmol), and tributylphosphine (0.030 mL) in 3 mL of  $\text{Na}_2\text{CO}_3$  solution (20 mg/mL) and 2 mL of ACN was stirred under  $\text{N}_2$  at room temperature overnight. After removing the organic solvent, the remaining aqueous solution was purified on reversed phase HPLC column eluted at 10 mL/min with a gradient of acetonitrile-water (5 to 15%) over 40 minutes to give 35 (10 mg, 31%) as a white solid: analytical RF-HPLC:  $t_R$  8.69 min with a gradient of 5 to 30% ACN in  $\text{H}_2\text{O}$  at a flow rate of 1 mL/min. purity, 97.9%;  $^1\text{H}$  NMR ( $\text{D}_2\text{O}$ ):  $\delta$  5.09 (d,  $J = 3.5$ , 2 H), 4.39 (d,  $J = 7.3$ , 2 H), 4.21 (t,  $J = 6.5$ , 2 H), 4.10 (d,  $J = 2.5$ , 2 H), 4.05 (m, 2 H), 3.96 (d,  $J = 2.6$ , 2 H), 3.88 (d,  $J = 2.5$ , 2 H), 3.85 (d,  $J = 3.0$ , 2 H), 3.82-3.57 (m, 32 H), 3.27 (s, 4 H), 3.23 (s, 4 H), 2.79 (t,  $J = 6.5$ , 4 H), 1.56 (br s, 4 H);  $^{13}\text{C}$  NMR ( $\text{D}_2\text{O}$ ):  $\delta$  173.1, 105.6, 103.4, 98.2, 96.0, 80.2, 78.3, 77.2, 75.3, 73.16, 71.8, 71.3, 70.9, 69.8, 69.4, 69.1, 65.4, 32.4, 40.5, 36.5, 34.6, 32.8; MS (ESI): m/e ( $M + \text{Na}^+$ ) Calcd. for  $\text{C}_{44}\text{H}_{80}\text{N}_2\text{O}_{28}\text{S}_2\text{Na}$ : 1171.4, obsd: 1172.5.

Compound 36Synthesis of Dimeric  $\alpha$ Gal Conjugate

This compound was prepared following the procedure described above for compound 35. Compound 19 (30 mg, 0.056 mmol) was conjugated with dimeric platform 24 (13.0 mg, 0.028 mmol) to give 36 as a white solid: analytical RF-HPLC:  $t_R$  11.3 min with a gradient of 5 to 30% ACN in H<sub>2</sub>O at a flow rate of 1 mL/min. purity, 97.4%; <sup>1</sup>H NMR (D<sub>2</sub>O):  $\delta$  5.19 (d,  $J$  = 3.5, 2 H), 4.53 (d,  $J$  = 8.8, 2 H), 4.22 (t,  $J$  = 3.9, 4 H), 4.13 (m, 2 H), 4.05-3.98 (m, 2 H), 3.91 (d,  $J$  = 2.7, 2 H), 3.88-3.66 (m, 42 H), 3.63 (t,  $J$  = 6.5, 4 H), 3.35 (t,  $J$  = 7.2, 8 H), 2.84 (t,  $J$  = 6.4, 4 H), 1.81 (m, 4 H); MS (ESI): m/e (M + Na<sup>+</sup>) Calcd. for C<sub>50</sub>H<sub>92</sub>N<sub>2</sub>O<sub>31</sub>S<sub>2</sub>Na: 1303.5, obsd: 1303.4.

Compound 37Synthesis of Tetrameric  $\alpha$ Gal Conjugate

The *tert*-butylthio protecting group of  $\alpha$ Gal 7 (30 mg, 0.052 mmol) was removed by reducing with tributylphosphine (25  $\mu$ L) in 5 mL of water at room temperature overnight. The reaction mixture was concentrated and dried under high vacuum overnight to remove any residual *tert*-butylthiol. The residue was dissolved in 5 mL of Na<sub>2</sub>CO<sub>3</sub> (10 mg/mL) solution in water/ACN (1:1). Tetrameric platform 25 (5.0 mg, 0.0074 mmol) was added and the resulted solution was stirred at room temperature overnight. After removing the organic solvent, the remaining aqueous solution was purified on a reverse phase HPLC column eluted at 10 mL/min with a gradient of acetonitrile-water (20 to 25%) over 40 minutes to give 37 (9.6 mg, 56%) as a white solid after lyophilization: MS (ESI): m/e (M/2 + Na<sup>+</sup>) Calcd. for C<sub>47</sub>H<sub>79</sub>O<sub>28</sub>S<sub>2</sub>Na: 1178.4, obsd.: 1178.4.

Compound 38Synthesis of Tetrameric  $\alpha$ Gal Conjugate

This compound was prepared following the procedure described above for compound 37. Compound 7 (22 mg, 0.038 mmol) was conjugated with platform 26 (7.0

mg, 0.0057 mmol). The product was purified on a reverse phase HPLC column with a gradient of acetonitrile-water (15 to 20%) over 40 minutes to yield 38 (13 mg, 80%) as a white solid: analytical RF-HPLC:  $t_R$  5.24 min with a gradient of 15 to 20% ACN in H<sub>2</sub>O at a flow rate of 1 mL/min, purity, 100%; MS (ESI): m/e (M/2 + Na<sup>+</sup>) Calcd. for C<sub>56</sub>H<sub>96</sub>N<sub>5</sub>O<sub>33</sub>S<sub>2</sub>Na: 1454.6, obsd.: 1454.5.

5

### Compound 39

#### Synthesis of Tetrameric $\alpha$ Gal Conjugate

10 This compound was prepared following the procedure described above for compound 38. The conjugation of compound 7 (22 mg, 0.038 mmol) with platform 27 (6.0 mg, 0.0048 mmol) yielded 39 (12 mg, 93%) as a white solid: analytical RF-HPLC:  $t_R$  11.32 min with a gradient of 15 to 20% ACN in H<sub>2</sub>O at a flow rate of 1 mL/min, purity, 100%; MS (ESI): m/e (M/2 + Na<sup>+</sup>) Calcd. for C<sub>53</sub>H<sub>87</sub>N<sub>4</sub>O<sub>32</sub>S<sub>2</sub>Na: 1379.1, obsd.: 1379.1.

15

### Compound 40

#### Synthesis of Tetrameric $\alpha$ Gal Conjugate

20

This conjugate is prepared by following the procedure described above for compound 38 using  $\alpha$ Gal 7 and platform 28.

### Compound 41

#### Synthesis of Tetrameric $\alpha$ Gal Conjugate 41

25 A mixture of *p*-aminophenyl 3-O- $\alpha$ -D-galactopyranosyl- $\alpha$ -D-galactopyranoside 22 (11 mg, 0.025 mmol), tetrameric platform 28, and NaHCO<sub>3</sub> (3 mg, 0.030 mmol) in 0.15 mL of H<sub>2</sub>O/CH<sub>3</sub>CN (1:1) was slightly shaken for 1.h. After addition of 0.15 mL of H<sub>2</sub>O, the reaction mixture was set at room temperature for 2 d and purified on reversed phase HPLC column eluted at 1 mL/min with a gradient of acetonitrile-water (0 to 30%) over 15 minutes

30

to yield 41(4.6 mg, 40%) as a white solid: MS (ESI): m/e (M/2 + 1) Calcd. for C<sub>60</sub>H<sub>95</sub>N<sub>7</sub>O<sub>29</sub>: 1377.6 obsd: 1377.9.

Compound 42

5                   Synthesis of Tetrameric  $\alpha$ Gal Conjugate

A solution of the beta isomer of  $\alpha$ Gal 7, 2-[2-(2-thioethoxy)ethoxy]ethyl 3-O-( $\beta$ -D-galactopyranosyl)- $\beta$ -D-galactopyranoside (30 mg, 0.061 mmol), platform 25 (5 mg, 0.0074 mmol), and tributylphosphine (0.10 mL) in 5 mL of Na<sub>2</sub>CO<sub>3</sub> (10 mg/mL) solution in water/ACN (1:1) was stirred at room temperature overnight. After removing the organic solvent, the remaining aqueous solution was purified on a reverse phase HPLC column eluted at 10 mL/min with a gradient of acetonitrile-water (20 to 25%) over 40 minutes to give 42 (2.4 mg, 14%) as a white solid: MS (ESI): m/e (M/2 + Na<sup>+</sup>) Calcd. for C<sub>47</sub>H<sub>79</sub>O<sub>28</sub>S<sub>2</sub>Na: 1178.4, obsd.: 1179.0.

15

Compound 43

Synthesis of Tetrameric  $\alpha$ Gal Conjugate

This conjugate was prepared by following the procedure described above for compound 38. The conjugation of compound 8 (25 mg, 0.043 mmol) with platform 27 (6.0 mg, 0.0048 mmol) yielded 43 (8.8 mg, 68%) as a white solid: analytical RF-HPLC: t<sub>R</sub> 6.84 min with a gradient of 15 to 20% ACN in H<sub>2</sub>O at a flow rate of 1 mL/min, purity, 100%; MS (ESI): m/e (M/2 + Na<sup>+</sup>) Calcd. for C<sub>53</sub>H<sub>87</sub>N<sub>4</sub>O<sub>32</sub>S<sub>2</sub>Na: 1379.4, obsd.: 1379.1.

25

Compound 44

Synthesis of Octameric  $\alpha$ Gal Conjugate

A solution of  $\alpha$ Gal 19 (23 mg, 0.429 mmol) and platform 29 (10 mg, 0.0043 mmol) in 2 mL of Na<sub>2</sub>CO<sub>3</sub> (10 mg/mL) solution in water/ACN (1:1) was stirred under N<sub>2</sub> at room temperature overnight. The reaction mixture was concentrated and purified on a reverse

phase HPLC column eluted at 10 mL/min with a gradient of acetonitrile-water (10 to 30%) over 40 minutes to give 44 (8.5 mg, 37%) as a white solid.

Compound 45

5

Synthesis of Octameric  $\alpha$ Gal Conjugate

This compound was prepared following the procedure described above for compound 44. Compound 19 (50 mg, 0.094 mmol) was conjugated with platform 30 (10 mg, 0.0018 mmol). The product was purified on a reverse phase HPLC column with a 10 gradient of acetonitrile-water (10 to 50%) over 40 minutes to yield 45 (10.8 mg, 67%) as a white solid: analytical RF-HPLC:  $t_R$  11.16 min with a gradient of 5 to 70% ACN in  $H_2O$  at a flow rate of 1 mL/min, purity, 100%.

Compound 46

15

Synthesis of Octameric  $\alpha$ Gal Conjugate

This compound was prepared following the procedure described above for compound 44. Compound 19 (691 mg, 1.41 mmol) was conjugated with platform 31 (280 mg, 0.141 mmol). The product was purified on a reverse phase HPLC column with 20 acetonitrile-water (19.5%) over 40 minutes to yield 46 (604 mg, 76%) as a white solid: analytical RF-HPLC:  $t_R$  9.16 min with a gradient of 15-25% ACN in  $H_2O$  at a flow rate of 1 mL/min, purity, 100%;  $^1H$  NMR ( $D_2O$ ):  $\delta$  5.13 (d,  $J = 3.8, 8$  H), 4.47 (d,  $J = 7.8, 8$  H), 4.12-4.16 (m, 24 H), 4.12-4.05 (m, 8 H), 4.00 (d,  $J = 0.8, 8$  H), 3.99-3.92 (m, 8 H), 3.86-3.64 (m, 144 H), 3.39-3.34 (m, 24 H), 3.28 (S, 8 H), 3.22-3.11 (m, 16 H), 2.79 (dd,  $J = 6.1, 10.6, 16$  H), 2.20 (t,  $J = 7.1, 8$  H), 1.82-1.68 (m, 8 H), 1.59-1.20 (m, 40 H);  $^{13}C$  NMR ( $D_2O$ ):  $\delta$  178.5, 178.4, 175.1, 174.2, 174.0, 159.3, 104.4, 97.0, 78.9, 76.6, 72.5, 71.4, 71.3, 71.1, 71.0, 70.9, 70.8, 70.3, 69.9, 66.5, 62.6, 55.9, 48.5, 48.1, 41.1, 40.8, 39.1, 38.9, 37.4, 37.0, 36.5, 33.0, 32.9, 32.6, 29.8, 29.6, 27.4, 26.7, 24.3; MS (ESI): m/e (M/3 + Na $^+$ ) Calcd. for (C<sub>224</sub>H<sub>400</sub>N<sub>18</sub>O<sub>126</sub>S<sub>8</sub>)/3 + Na: 1895.7, obsd.: 1895.3.

30

Compound 47Synthesis of Octameric  $\alpha$ Gal Conjugate

This compound was prepared following the procedure described above for  
5 compound 44. Compound 19 (29 mg, 0.055 mmol) was conjugated with platform 32 (10 mg, 0.0055 mmol). The product was purified on reverse phase HPLC column with a gradient of acetonitrile-water (15 to 20%) over 40 minutes to yield 47 (20 mg, 65%) as a white solid: analytical RF-HPLC:  $t_R$  11.35 min with a gradient of 15 to 25% ACN in H<sub>2</sub>O at a flow rate of 1 mL/min. purity, 82%; MS (ESI): m/e (M/3 + Na<sup>+</sup>) Calcd. for  
10 (C<sub>232</sub>H<sub>416</sub>N<sub>18</sub>O<sub>126</sub>S<sub>8</sub>)/3 + Na: 1933.1, obsd.: 1932.1.

Example 4: In vitro characterization of  $\alpha$ Gal conjugatesMaterials and Methods

15 *Antibodies.* Blood was drawn from healthy normal volunteers. Plasma was separated by centrifugation and allowed to clot. Fibrin was removed and plasma was used immediately or stored in aliquots at -70°C. Rhesus monkey serum (California Regional Primate Research Center, Davis, CA) was obtained from blood drawn into vacutainer tubes and allowed to clot. After serum was separated by centrifugation, it was pooled, aliquoted and stored at -20°C or -70°C. In some experiments, sera was heat-inactivated at 56°C for  
20 30 minutes to destroy complement hemolytic activity. Antibodies to the  $\alpha$ Gal epitope were affinity purified on an  $\alpha$ Gal-Sepharose column, which was prepared by coupling  $\alpha$ Gal-SH to maleimide-Sepharose (Pierce) through Michael addition chemistry at 10 mg/mL resin. Up to 20 mL pooled NHS or normal monkey serum (NMS) was applied to a 2 mL volume  
25 of packed  $\alpha$ Gal-Sepharose. After the flow through was collected, the column was washed with 10-20 column volumes or until A<sub>280</sub> reached baseline values and eluted with 0.1 M triethanolamine, pH 11.5 into tubes containing 1M Tris, pH 8.0. The column was immediately washed with 10-20 volumes of phosphate-buffered saline (PBS). Fractions were assessed for protein concentration by Bradford assay. Peak fractions were pooled and  
30 dialyzed against PBS. Affinity-purified anti- $\alpha$ Gal Ig was negatively selected for IgG by purification over an MBP column (Pierce, Rockford, IL) which removed IgM anti- $\alpha$ Gal

antibodies. IgM anti- $\alpha$ Gal was negatively selected by purification over a protein G-Sepharose column (Boehringer Mannheim, Indianapolis, IN) which removed IgG anti- $\alpha$ Gal antibodies. An elution profile of anti- $\alpha$ Gal Ig from an  $\alpha$ Gal affinity column is shown in Figure 16.

5

*SDS-PAGE and Immunoblot Analysis.* Antibody-containing fractions and pools were resolved by 4-12% SDS-PAGE (Novex, San Diego, CA). Proteins were electrophoretically transferred to PROTRAN™ pure nitrocellulose membranes (Schleicher and Schuell, Keene, NH) using XCELL II™ Blot Module blot system (Novex).

10 Membranes were blocked with 2% non-fat dry milk (NFDM) in PBS and probed with anti-human IgG or IgM coupled to alkaline phosphatase (Jackson ImmunoResearch, West Grove, PA) or anti-monkey IgG or IgM coupled to alkaline phosphatase (Advanced Chem Tech, Louisville, KY). Second step antibody was developed with Western Blue Stabilized Substrate for alkaline phosphatase (Promega Corporation, Madison, WI).

15

*ELISA for anti- $\alpha$ Gal antibodies.*  $\alpha$ Gal-SH was coupled to maleimide-BSA (bovine serum albumin) (Pierce) at a 2:1 ratio (w/w) according to manufacturer's protocol. The ratio of  $\alpha$ Gal molecules coupled per BSA molecule was 10-12:1 or 25:1. Alternatively,  $\alpha$ Gal-BSA or  $\alpha$ Gal-HSA (human serum albumin) was purchased with C3 or C14 linker groups (Dextra, Redding, England).  $\alpha$ Gal-BSA (100  $\mu$ L at 5  $\mu$ g/mL in PBS) was adsorbed onto 96 well plates for 18 hours at 4°C. Plates were blocked with 2% NFDM in PBS at 4°C for at least 48 hours prior to use. Plates were stable for at least 3 months. New lots of plates were compared with binding efficacy of the original lot using pooled standard serum. Pooled standard sera, individual sera or affinity purified anti- $\alpha$ Gal Ig were titrated. Serum (100  $\mu$ L neat - 1/256 diluted in HBSA) or affinity-purified anti- $\alpha$ Gal IgG (100  $\mu$ L of serial two-fold dilutions from 2 mg/mL - 1  $\mu$ g/mL in Hank's balanced salt solution without Ca<sup>+2</sup> or Mg<sup>+2</sup> (HBSA)) were incubated in  $\alpha$ Gal-BSA coated wells for 60 minutes at 20°C. After washing, anti- $\alpha$ Gal Ig was developed with predetermined saturating concentrations (100  $\mu$ L, usually 1:1000 dilution) of anti-monkey or anti-human IgG or IgM coupled to alkaline phosphatase for 60 minutes at 20°C. After washing the wells 5 times with wash

30

buffer (1% Tween 20 in PBS), plates were developed with 100  $\mu$ L PPMP (phenolphthalein monophosphate) (Sigma) for 5-20 minutes at 20°C. Reactions were stopped by addition of 100  $\mu$ L 0.2M Na<sub>2</sub>HPO<sub>4</sub> and plates read at A<sub>550</sub> (PowerWave 340 Microplate Spectrophotometer, Bio-Tek, Winooski, Vermont).

5

*$\alpha$ Gal Conjugates.*  $\alpha$ Gal (galactose ( $\alpha$ 1, 3, galactose) epitopes were synthesized at a multigram scale as described in Example 1 and were coupled to a well-defined organic platform as described in Example 3.

10            *Competition ELISA.* Serum or affinity purified anti- $\alpha$ Gal Ig preparations were titered by ELISA and the 50% binding concentration was determined. For serum, the 50% binding point was reached at a serum dilution of ~1:5 while for affinity-purified Ig, the 50% dilution binding concentration was ~12.5  $\mu$ g/mL. Serum or Ig (50  $\mu$ L) was incubated with an equal volume of HBSA containing inhibitor which was serially diluted in a two-fold manner from 4 mg/mL to 10  $\mu$ g/mL or buffer alone for 60 minutes at 20°C. Anti- $\alpha$ Gal Ig or serum  $\pm$  inhibitor was then added to  $\alpha$ Gal-BSA-coated plates and Ig binding was assessed as described. Percent inhibition of anti-digal binding was calculated as follows: [(OD<sub>550</sub> Ig source + INH) - OD<sub>550</sub> blank / (OD<sub>550</sub> Ig source - INH) - OD<sub>550</sub> blank] x 100.  
(INH = inhibitor)

15

20            *ELISpot assay.* Spleens from normal rhesus monkeys were minced and prepared as single cell suspension using deburred frosted glass slides. Contaminating erythrocytes were hypotonically lysed and mononuclear cells (MNC) isolated by Ficoll-hypaque density gradient centrifugation. MNC (100  $\mu$ L) were added in serial two-fold dilutions from 10<sup>4</sup>/cells/mL to 5 x 10<sup>2</sup> cells/mL in quadruplicate to ELISA plates bearing  $\alpha$ Gal-BSA or anti-monkey IgG or IgM. Plates were incubated overnight at 37°C in a humidified atmosphere with 5% CO<sub>2</sub> and then washed. The footprint of secreted anti- $\alpha$ Gal Ig bound to  $\alpha$ Gal-BSA was developed by incubation with goat anti-monkey IgG or IgM coupled to biotin (Advanced ChemTech) for 60 minutes at 37°C followed by the addition of ExtrAvidin-alkaline phosphatase (Sigma). Alkaline phosphatase substrate B (100  $\mu$ L at 1:100 dilution, Bio-Rad, Hercules, CA) was added and incubation continued overnight at

25

20°C. Total Ig-producing cells were similarly determined. The footprints were quantified using a Microtek ScanMaker III flat-bed scanner and personal computer utilizing the Image-Pro imaging software (Media Cybernetics, Univ. Rochester Medical School, Rochester, NY). The ratio of anti- $\alpha$ Gal IgG- or IgM-producing cells/total IgG- or IgM-producing cells were calculated.

5                    *Cytotoxicity assays.* The porcine kidney epithelial cell line PK-15 and porcine aortic endothelial cells (PAEC) (ATCC, 10801 University Blvd., Manassas, VA 20110-2209) were cultured as directed. For the assay, cells were removed with trypsin - EDTA and replated subconfluently in 96 well plates or on coverslips in 24-well plates. While still subconfluent (within 2 days of replating), cells were used in cytotoxicity assays. Neat, complement-sufficient serum was incubated with inhibitor as described for 60 minutes at 10 4°C. Serum was then added to wells containing subconfluent cells from which medium had been aspirated immediately prior to serum addition. Wells were incubated with serum ± inhibitor for 60-90 minutes at 37°C. Wells were rinsed and cell death was visualized 15 using a Live/Dead kit (Molecular Probes, Eugene, OR) and quantified microscopically in 10 high powered fields or by counting 250 cells. For some experiments, cells were non-enzymatically removed from flasks with cell dissociation solution (Sigma) and single cell suspensions prepared. Assays were performed as for adherent cells except that cytotoxicity 20 was quantified by flow cytometry on a Becton-Dickinson FACScalibur.

## Results

### *Antigenic activity of $\alpha$ Gal epitope*

25                  The synthetically prepared  $\alpha$ Gal epitope (Figure 2) was antigenically active, as demonstrated by its ability (when coupled to Sepharose) to remove >95% of anti- $\alpha$ Gal Ig from normal rhesus monkey or human serum as measured by FACS.

30                  *Activity of tetrameric conjugates.* We tested the  $\alpha$ Gal tetrameric platform constructs which included the PITG platform (compound (cpd) 38) and BMTG (cpd 37) platforms as described in Example 2 and found them to be equivalent in their ability to inhibit Ab from binding to the  $\alpha$ Gal epitope in the ELISA. Cpd 38 (LJP712) bound anti- $\alpha$ Gal Ig and inhibited the binding of IgG anti- $\alpha$ Gal to the  $\alpha$ Gal-expressing porcine kidney

epithelial cell line PK-15 and to BSA- $\alpha$ Gal adsorbed onto ELISA wells at ~1 mM. The binding of affinity purified IgM anti- $\alpha$ Gal was inhibited 1000-fold less well by cpd 38 than was the IgG anti- $\alpha$ Gal.

Activity of octameric conjugates. Octameric conjugates (as described in Example 2) were tested. Octameric conjugate cpd 44 (also referred to as LJP 719) was tested *in vitro* for its ability to inhibit in serum the anti- $\alpha$ Gal IgM binding to BSA- $\alpha$ Gal. ELISA analysis showed that the  $\alpha$ Gal epitope when presented on a platform as an octamer inhibited both IgG and IgM anti- $\alpha$ Gal in serum from binding to BSA- $\alpha$ Gal or to the  $\alpha$ Gal-expressing porcine kidney epithelial cell line PK-15 and was 5-10 fold more efficient at inhibiting the IgM anti- $\alpha$ Gal binding to the  $\alpha$ Gal epitope, as shown in Figure 18. This supported our hypothesis that valency of the toleragen was very important in binding the lower affinity IgM molecules.

#### Example 5: In vivo evaluation of conjugates

15

The *in vivo* efficacy of the toleragens was tested in a dose-escalation study in rhesus monkeys which were treated IV with tetrameric or octameric toleragen or buffer.

Six male rhesus monkeys (3.5-4 kg) were housed at the California Regional Primate Research Center (CRPRC), Davis, CA. All experimental protocols met CRPRC IACUC (Institutional Animal Care and Use Committee) standards. Monkeys were bled for baseline clinical values and anti- $\alpha$ Gal antibody levels. Monkeys were bled for baseline clinical values. Four monkeys were treated IV daily with 2-20 mg/kg of tetravalent platform LJP 712 (cpd 38). Two monkeys received PBS alone intravenously (IV) as a control. Monkeys were bled weekly (5 mL) immediately prior to the IV injection in those animals treated for 25 60 days with LJP 712 at 2 mg/kg. When monkeys received 10 mg/kg or 20 mg/kg of tetrameric LJP 712 or 20 mg/kg octameric LJP 920 (cpd 46), treatment was for 5-7 days and animals were bled every 2-3 days for 3 mL. Serum samples were analyzed by ELISA for anti- $\alpha$ Gal IgG and IgM. In one experiment, two monkeys were treated IV daily for 10 days with 20 mg/kg octameric platform LJP 719. In another experiment, monkeys were 30 treated daily IV with octameric LJP 920 at 20 mg/kg.

5           *Tetrameric conjugates.* To test the *in vivo* efficacy of LJP 712, the tetravalent toleragen at doses high enough to create a molar excess of toleragen to anti- $\alpha$ Gal antibody in the plasma based on 1% of circulating antibody being specific for  $\alpha$ Gal was used to treat monkeys. Monkeys were treated IV daily with 2 mg/kg of LJP 712 (n=4) or buffer (PBS) (n=2) for 60 days as described above. Blood was drawn weekly and serum tested by ELISA for IgG and IgM anti- $\alpha$ Gal. LJP 712 was well-tolerated and did not activate either the classical or alternative complement pathways *in vitro*, as shown in Figures 20 and 21, respectively. There was no statistically significant diminution of anti- $\alpha$ Gal Ig responses.

10          We next sought to determine whether higher doses of LJP 712 were able to effect clearance of anti- $\alpha$ Gal Ab from the circulation using shorter term IV dosing modalities. When the dose was increased to 10 mg/kg LJP 712, little diminution of either IgG or IgM anti- $\alpha$ Gal was observed. By contrast, daily IV treatment with 20 mg/kg LJP 712 resulted in the diminution of the anti- $\alpha$ Gal IgG response by up to 24% (p<0.05) by day 8 of treatment and anti- $\alpha$ Gal IgM levels by up to 12% (p=NS), as shown in Figure 19.

15          *Octameric conjugates*

20          We next determined whether treatment of rhesus monkeys for 7 days with the octameric toleragen LJP 920 led to a diminution in serum levels of anti- $\alpha$ Gal Ab. Two monkeys were treated IV daily with PBS and two were treated IV daily with LJP 920 (cpd 46) at 20 mg/kg, a dose which for tetrameric toleragen had shown a diminution in circulating IgG anti- $\alpha$ Gal but not IgM anti- $\alpha$ Gal. Serum samples were prepared from blood drawn immediately prior to drug or control administration on day 0 (prebleed) and on days 3 and 6 (24 hours post-drug administration). Serum was also prepared on day 8, 24 hours after the last dose with no subsequent dosing administered. LJP 920 (cpd 46) was well-tolerated in the treated animals with no untoward effects as observed by veterinary staff. At day 8, IgG anti- $\alpha$ Gal levels were decreased by 11%, similar to the levels seen with tetramer. Control animals showed little change (Fig. 22A). Similarly, there was a diminution of 18% in IgM anti- $\alpha$ Gal levels in one monkey and 5% in the replicate animal. By contrast, IgM anti- $\alpha$ Gal levels in the control animals did not change in one animal and increased in the replicate animal, as shown in Figure 22B. That the octamer is more efficient than tetramer at clearing IgM anti- $\alpha$ Gal is shown in Fig. 23. These data show that increased valency results not only in a more efficacious molecule *in vitro* but also *in vivo*.

**Example 6: In vivo evaluation of octameric conjugate: induction of tolerance gal α1,3-galactosyltransferase knockout mice using an octameric gal α1-3gal conjugate, LJP 920**

5

The goal of this experiment was to determine whether treatment of GalT knock-out mice with octameric digal (used interchangeably with αGal) conjugate *LJP 920* would induce digal (i.e., αGal)-specific tolerance.

α1,3-galactosyltransferase knockout mice (Thall et al. (1995) *J. Biol. Chem.* 270:21437-21440) (GalT KO) are unable to synthesize the Galα1-3Gal disaccharide (digal.) and as such are similar to humans, apes and Old world monkeys in that they spontaneously form antibodies that recognize terminal Galα1-3Gal epitopes. The GalT KO mouse therefore is an extremely useful system in which to test potential methods of diminishing natural anti- Galα1-3Gal antibodies. Yang et al. (1998) *J. Exp. Med.* 187:1335-1342.

**Materials and Methods**

*ELISA for anti αGal antibody.* Immunoassay plates (Costar #3590) were coated overnight at 4°C with 100 µl/well digal (i.e., αGal)-bovine serum albumin (BSA-digal) at 5 µg/ml in phosphate buffered saline (PBS). Plates were washed with PBS and remaining protein-binding sites blocked overnight at 4°C with 250 µl/well 5% non-fat dried milk in PBS. Serum samples were diluted in Hanks Balanced salt solution (HBSS) containing 0.5% BSA (HBSA). Blocked plates were washed with PBS-0.1% Tween 20 and 50 µl of serum sample dilutions added. Plates were incubated for 1 hour at room temperature. Plates were washed with PBS-0.1% Tween 20. Alkaline phosphatase-conjugated goat anti-mouse IgG or IgM (Jackson #115-055-146 or 115-055-075, 1/1000 in HBSA) was added (100 µl/well) and plates were incubated for 1 hour at room temperature. Plates were washed with PBS-0.1% Tween 20. Phenolphthalein monophosphate (1:26 in distilled water, 100 µl per well) was added and the plates incubated at room temperature. Optical

density was read at 550 nm after 10 and 30 minutes incubation on a PowerWave 340 Microplate spectrophotometer.

*ELISpot for anti-digal specific antibody forming cells.* Immunoassay plates were coated with BSA-digal and blocked as above. Blocked plates were washed 6x with PBS-  
5 0.1% Tween 20, 2x with PBS and once with RPMI-1640 (Sigma) containing 1% fetal bovine serum (FBS, Gibco #16000-044), 2 mM glutamine (Gibco #25030-081), 1x antibiotics (Gibco #15240-062) and 10 mM HEPES (Gibco #15630-080) (RPMI-1).

Spleens were removed from mice and disaggregated into RPMI-1 by crushing between two ground glass slides. Peritoneal cells were obtained by washing the peritoneal cavity with  
10 RPMI-1. Cells were washed two times in RPMI-1 and resuspended in the same medium containing 10% FBS (RPMI-10). Dilutions of cells were plated onto coated plates in a final volume of 100 $\mu$ l RPMI-10. Plates were incubated overnight at 37°C in 5% CO<sub>2</sub>, 95% humidity.

Plates were washed 6x with PBS-0.1% Tween 20 and incubated with 100  $\mu$ l biotin-conjugated anti-IgM or anti-IgG (Jackson #115-065-020 or 115-065-008, 1/1000 in PBS containing 10% goat serum, 1% fish gelatin and 0.05% Tween-20) for 1 hour at 37°C.

Plates were washed 6x with PBS-0.1% Tween 20 and incubated with 100  $\mu$ l ExtrAvidin-alkaline phosphatase (Sigma, #E2636, 1/1000 in PBS containing 10% goat serum, 1% fish gelatin and 0.05% Tween-20) for 1 hour at 37°C. Plates were washed 6x with PBS-0.1%  
20 Tween 20 and incubated with 100  $\mu$ l alkaline phosphatase substrate B, 1/100 in developing buffer (Biorad #170-6432) overnight at room temperature in the dark. Plates were then rinsed with distilled water, air-dried, and spots counted manually by microscopic examination.

*Experimental protocol.* GalT KO mice were obtained from John Lowe (University of Michigan). Mice (15-16 weeks old) were treated daily (excluding Sundays) for 15 weeks i.p. with 400  $\mu$ g *LJP* 920 dissolved in phosphate buffered saline (PBS) or PBS alone. Blood samples were collected prior to treatment and weekly thereafter. After 15 weeks *LJP* 920 treatment was halted and mice were immunized with 1x10<sup>9</sup> rabbit red blood cells (rRBC) i.p. Immunization was necessary for the detection of anti-digal specific antibody forming cells (AFC) and allowed determination of whether tolerance had been induced. Eight days later animals were sacrificed and spleen and peritoneal cells assayed

for digal-specific AFC by ELISpot. Serum samples were assayed for anti-digal-antibodies by ELISA. For comparison, wild type C57Bl/6 x DBA/2 mice were also tested. These mice express the  $\alpha$ 1,3-galactosyltransferase enzyme and so do not make anti-digal antibodies. Values from these mice represent background in ELISA assays.

5

### Results

*Serum anti-digal antibody levels.* Data from sequential bleeds were analyzed by repeated measures ANOVA. IgM and IgG anti-digal antibodies were significantly reduced in *LJP* 920 treated animals relative to placebo treated animals ( $p \leq 0.001$  in both cases; 10 Figures 27A and 27B).

At 15 weeks, prior to rRBC immunization, levels of IgM anti-digal antibodies were significantly decreased in *LJP* 920 treated animals relative to placebo treated animals (mean OD 0.124 vs 0.399,  $p=0.0004$ , ANOVA; Figure 28A). Similarly, levels of IgG anti-digal antibodies were significantly decreased in *LJP* 920 treated animals relative to placebo 15 treated animals (mean OD 0.079 vs 0.179,  $p=0.0005$ , ANOVA; Figure 28B). In *LJP* 920 treated animals, levels of IgM and IgG anti-digal were not significantly different from background (IgM: WT, mean OD 0.061 vs *LJP* 920, mean OD 0.124; IgG: WT, mean OD 0.055 vs *LJP* 920, mean OD 0.079; Figures 28A and B).

Following immunization with rRBC, levels of IgM anti digal antibodies were significantly lower in *LJP* 920 treated animals vs. placebo treated animals (*LJP* 920 mean 20 OD 0.658 vs placebo mean 1.097,  $p=0.008$ , ANOVA; Figure 28A). Levels of IgG anti-digal antibodies were similarly lower in *LJP* 920 treated animals (*LJP* 920 mean OD 0.335 vs placebo mean 0.481,  $p=0.038$ , ANOVA; Figure 28B). Both IgM and IgG anti-digal 25 antibody levels in *LJP* 920 treated animals were significantly increased following rRBC immunization relative to WT controls however (IgM: WT, mean OD 0.062 vs *LJP* 920, mean OD 0.658,  $p=0.001$ ; IgG: WT, mean OD 0.058 vs *LJP* 920, mean OD 0.335,  $p=0.001$ , ANOVA; Figures 28A and B).

*Digal-specific AFC.* The frequency of digal-specific AFC following rRBC immunization was determined by ELISpot analysis. IgM anti-digal AFC were significantly lower in *LJP* 920 treated animals compared with placebo treated animals ( $p=0.02$ , 30 ANOVA; Figure 29); however the number of AFC did not decrease to background levels.

Neither anti-digal-specific AFC in peritoneal cells nor IgG anti-digal secreting cells in the spleen were detected.

These results indicate that treatment with LJP920 is highly effective at decreasing the level of both IgM and IgG anti- $\alpha$ Gal antibodies. That this result reflects tolerance induced by the toleragen is supported by the observation of a significant decrease in  $\alpha$ Gal-specific AFC following LJP920 treatment.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be apparent to those skilled in the art that certain changes and modifications will be practiced. Therefore, the description and examples should not be construed as limiting the scope of the invention, which is delineated by the appended claims.

CLAIMS

We claim:

1. A conjugate comprising a valency platform molecule and an  $\alpha$ Gal epitope, wherein the valency platform molecule has a valency from two to 128.

5

2. The conjugate of claim 1, wherein the valency platform molecule has a valency of two.

3. The conjugate of claim 1, wherein the valency platform molecule has a valency of four.

10 4. The conjugate of claim 1, wherein the valency platform molecule has a valency of eight.

5. The conjugate of claim 1, wherein the valency platform molecule has a valency of 16.

15 6. The conjugate of claim 3, wherein the valency platform molecule is compound 26.

7. The conjugate of claim 4, wherein the valency platform molecule is compound 31.

20 8. A conjugate according to claim 3, wherein the conjugate has the structure of compound 38.

9. A conjugate according to claim 4, wherein the conjugate has the structure of compound 46.

25 10. A conjugate according to claim 1, wherein the  $\alpha$ Gal epitope is 2-[2-(2-acetylthioethoxy)ethoxy]ethyl 3-O-( $\alpha$ -D-galactopyranosyl)- $\beta$ -D-galactopyranoside.

11. A conjugate comprising a valency platform molecule and an  $\alpha$ Gal epitope, wherein the valency platform molecule has a valency of at least two.

30

12. A composition comprising the conjugate of claim 1.

13. A composition comprising the conjugate of claim 3.

14. A composition comprising the conjugate of claim 4.

5

15. A composition comprising the conjugate of claim 9.

16. A method of reducing circulating levels of anti- $\alpha$ Gal antibody in an individual, comprising administering an effective amount of the conjugate of claim 1 to the individual.

10

17. A method of reducing circulating levels of anti- $\alpha$ Gal antibody in an individual, comprising administering an effective amount of the conjugate of claim 3 to the individual.

15

18. A method of reducing circulating levels of anti- $\alpha$ Gal antibody in an individual, comprising administering an effective amount of the conjugate of claim 7 to the individual.

19. A method of reducing circulating levels of anti- $\alpha$ Gal antibody in an individual, comprising administering the composition of claim 9 to the individual in an amount sufficient to reduce circulating levels of anti- $\alpha$ Gal antibody in the individual.

20

20. A method of neutralizing circulating anti- $\alpha$ Gal antibody in an individual, comprising administering the composition of claim 1 to the individual.

21. A method of inducing tolerance to  $\alpha$ Gal in an individual, comprising administering an effective amount of the conjugate of claim 1 to the individual.

25

22. A method of inducing tolerance to  $\alpha$ Gal in an individual, comprising administering an effective amount of the conjugate of claim 9 to the individual.

30

23. A method of detecting an antibody which specifically binds to the conjugate of claim 1 in a biological sample, comprising (a) contacting antibody in the sample with the conjugate

of claim 1 under conditions that permit the formation of a stable antigen-antibody complex; and (b) detecting stable complex, if any, formed in step (a).

24. The method of claim 23, wherein the antibody is expressed on the surface of a B cell.

5

25. A method of performing a xenotransplantation in an individual, comprising the steps of:

(a) introducing xenotissue to an individual, wherein the xenotissue comprises an  $\alpha$  Gal epitope; and

(b) administering the conjugate of claim 1 to the individual.

10

26. The method of claim 25, wherein step (b) is performed at least about 30 days before step (a).

15

27. A method of performing a xenotransplantation in an individual, comprising the steps of:

(a) introducing xenotissue to an individual, wherein the xenotissue comprises an  $\alpha$  Gal epitope; and

(b) administering the conjugate of claim 9 to the individual.

20

28. The method of claim 27, wherein step (b) is performed at least about 30 days before step (a).

25

29. A method of suppressing rejection of a transplanted tissue comprising an  $\alpha$ Gal epitope in an individual, said method comprising administering the conjugate of claim 1 to the individual in an amount sufficient to suppress rejection.

30. A method of suppressing rejection of a transplanted tissue comprising an  $\alpha$  Gal epitope in an individual, said method comprising administering the conjugate of claim 9 to the individual in an amount sufficient to suppress rejection.

1 / 34

Fig. 1





Fig. 2



3/34





Fig. 3

# General Conjugation Chemistry

## Method 1:



## Method 2:




Fig. 4

$R = H, t\text{BBS}, \text{ or } COCH_3$   
 $X = I, Br, \text{ or } Cl$

## General Conjugation Chemistry

Method 3:










Fig. 5

Fig. 6

## Dimeric Platform:



## Tetrameric Platform:



7 / 34








Fig. 8

Monomeric Conjugate:




Dimeric Conjugate:




Tetrameric Conjugate:

Fig. 9



37



29

38

## Tetrameric Conjugate:





Fig. 10

Tetrameric Conjugate:





Fig. 11

12/34

## Octomeric Conjugate:




Fig. 12

13/34

## Octomeric Conjugate:




Fig. 13

45

14/34

## Octomeric Conjugate:




Fig. 14

15/34

## Octomeric Conjugate:




Fig. 15

16/34

### Affinity Purification of anti-diGal Ig on alpha 1,3 DiGal Column




Fig. 16

## Affinity Purified IgG binding to PK-15 Cells




Fig. 17A

## Affinity Purified IgM binding to PK-15 Cells





Fig. 17B

19/34

**Fig. 18**

20/34

LJP 712 causes decreased circulating  
anti- $\alpha$ Gal IgG in primate model




Fig. 19 Days of Toleragen treatment

21/34

LJP 712 does not activate  
the classical pathway of complement




Fig. 20

22/23

LJP 712 does not activate  
the alternative pathway of complement




Fig. 21

µg activator/ml

23/34




Fig. 22A




Fig. 22B

25/34




Fig. 23

26 / 34





Fig. 24

27 / 34

Fig. 25



28 / 34

Fig. 26A










Fig. 26B



30/34




Fig. 27A

31 / 34




Fig. 27B

32/34




Fig. 28A

33/34




Fig. 28B

34/34




Fig. 29